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ABSTRACT 
Soyoung Park 
 
IN VIVO ANALYSIS OF HUMAN LHX3 ENHANCER REGULATION 
 
The LHX3 transcription factor is essential for pituitary gland and nervous system 
development in mammals. In humans, mutations in the LHX3 gene underlie combined 
pituitary hormone deficiency (CPHD) disease featuring deficits in anterior pituitary 
hormones and defects in the nervous system. The mechanisms that control temporal and 
spatial expression of the LHX3 gene are poorly understood. The proximal promoters of 
the human LHX3 gene are insufficient to guide expression in vivo and downstream 
elements including a conserved 7.9 kilobase (kb) enhancer region appear to play a role in 
tissue-specific expression in the pituitary and nervous system. In this study, I 
characterized the activity of this downstream enhancer region in regulating gene 
expression at the cellular level during development. Human LHX3 enhancer-driven Cre 
reporter transgenic mice were generated to facilitate studies of enhancer actions. The 
downstream LHX3 enhancer primarily guides gene transcription in αGSU-expressing 
cells secreting the TSHβ, LHβ or FSHβ hormones and expressing the GATA2 and SF1 
transcription factors. In the developing nervous system, the enhancer serves as a targeting 
module for expression specifically in V2a interneurons. These results demonstrate that 
the downstream LHX3 enhancer is important in specific endocrine and neural cell types 
but also indicate that additional regulatory elements are likely involved in LHX3 gene 
  vii 
expression in other cell types. Further, these studies demonstrate significant gonadotrope 
cell heterogeneity during pituitary development, providing insights into the cellular 
physiology of this key reproductive regulatory cell. The human LHX3 enhancer-driven 
Cre reporter transgenic mice provide a valuable tool for further developmental studies of 
cell determination and differentiation in the pituitary and nervous system. Furthermore 
understanding the regulation of human LHX3 gene will help develop tools to better 
diagnose and treat pituitary CPHD disease. 
 
 
Simon J. Rhodes Ph.D., Chair 
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CHAPTER ONE 
INTRODUCTION  
1.1 The Pituitary Gland and its Hormones 
The pituitary, or hypophysis, is located at the base of the brain and it is situated 
within the sella turcica which is formed by the sphenoid bone. The pituitary is crucial for 
the maintenance of various physiological processes including growth, lactation, 
homeostasis, reproduction, metabolism, and stress response. The mature pituitary is 
composed of three lobes: the posterior lobe, the intermediate lobe, and the anterior lobe. 
The primary physiological role of the pituitary is to secrete hormones. The 
posterior lobe consists of an extension of magnocellular neurosecretory cells of the 
hypothalamus that synthesize peptide hormones such as oxytocin (OT) and arginine 
vasopressin (AVP) (Scully and Rosenfeld, 2002). OT and AVP are transported by axon 
terminals to the posterior lobe of the pituitary gland from the hypothalamus and released 
into bloodstream. AVP regulates osmotic balance by acting to increase water absorption 
in the collecting ducts of the kidney. OT is released after labor to stimulate muscle 
contraction, and in response to a positive feedback loop to stimulate milk ejection from 
the mammary glands.  
Within the intermediate lobe of the pituitary, melanotropes secrete alpha 
melanocyte-stimulating hormone (αMSH). αMSH hormone is a 13 amino acid peptide 
produced by proteolytic processing of its pro-opiomelanocortin pro-hormone encoded by 
the pro-opiomelanocortin (POMC) gene. αMSH has functions in skin pigmentation and 
other functions in lower vertebrates [reviewed in (Roubos et al., 2010)]. The human 
intermediate lobe is less developed than in many other species, consisting of a thin layer 
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of cells between the posterior and anterior lobes, and produces less αMSH than 
amphibians [reviewed in (Catania et al., 2000)]. 
The anterior pituitary is a critical component of endocrine physiology and it 
contains five distinct hormone-secreting cell types (Figure 1.1). Somatotropes secrete 
growth hormone (GH) that regulates linear growth and some metabolic activities. 
Lactotropes produce prolactin (PRL), regulating milk production and other reproductive 
functions. Corticotropes secrete adrenocorticotrophic hormone (ACTH): a proteolytic 
product of the POMC pre-hormone encoded by the POMC gene. ACTH regulates 
metabolism and other activities by stimulating the functions of the hormone-secreting 
adrenal gland cortex. Thyrotropes produce thyroid-stimulating hormone (TSH), which 
promotes thyroid follicle development and thyroid hormone secretion which 
subsequently control multiple homeostatic functions. Gonadotropes produce luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH), which act on the gonads to 
initiate sexual maturation and reproductive functions [reviewed in (Zhu et al., 2007)]. 
TSH, FSH, LH are heterodimeric glycoproteins composed of a common alpha 
glycoprotein subunit (αGSU) and a unique beta subunit [e.g. TSHβ; reviewed in (Perez-
Castro et al., 2012)]. During early development in mammals, anterior pituitary hormone 
cell lineages are located in distinct areas of the gland. Corticotropes and gonadotropes are 
more concentrated in the ventral area; and somatotropes and lactotropes are enriched in 
the dorsal regions of the anterior pituitary. Thyrotropes are found in two independent 
areas during development; the rostral tip and the caudomedial region (Lin et al., 1994; 
Dasen et al., 1999; Kioussi et al., 1999). 
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The hypothalamus maintains control of anterior and intermediate pituitary 
hormone production by the secretion of releasing and inhibiting hormones from the 
median eminence. These regulatory hormones are transported through the hypophyseal 
portal blood system and bind to specific anterior pituitary cell surface receptors. For 
example, GH-releasing hormone (GHRH) binds to the GH-releasing hormone receptor 
located on anterior pituitary somatotropes resulting in GH hormone synthesis and release. 
Similarly, gonadotropin-releasing hormone (GnRH) is released from the hypothalamus 
and binds to the GnRH-receptor on the gonadotrope cell surface to promote secretion of 
LH and FSH.  
1.2 Pituitary Development 
The mature pituitary derives from two distinct components, the neurohypophysis 
and the adenohypophysis, which have different embryonic origins. The neurohypophysis 
is derived from the ventral diencephalon and is therefore neuroectodermal in origin. It 
includes the posterior pituitary, the infundibular (pituitary) stalk which is connected to 
the hypothalamus, and the median eminence. The adenohypophysis develops from from 
an invagination of the oral ectoderm to form a rudimentary Rathke’s pouch, the 
rudimentary structure that will form the anterior pituitary, the intermediate pituitary, and 
the pars tuberalis (an extension of the anterior pituitary that wraps around the pituitary 
stalk) (Figure 1.1). (Watanabe, 1982a). The end of the anterior neural ridge in the oral 
ectoderm becomes the primordium of the anterior and intermediate lobes of the pituitary. 
The adjacent neural plate becomes the hypothalamus and the posterior lobe of pituitary. 
In the mouse, the first sign of pituitary development occurs at e7.5 with the 
development of the hypophyseal placode. At e8.5, the anterior neural tube bends and 
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extends rapidly. At e9, the placode forms the rudimentary Rathke’s pouch. Ectodermal 
invagination brings physical contact between the ventral diencephalon and oral ectoderm. 
By e10.5, a restricted region of ventral diencephalon above Rathke’s pouch forms the 
infundibulum that becomes the posterior pituitary and the pituitary stalk. At e12.5, 
Rathke’s pouch is morphologically developed (Kawamura and Kikuyama, 1998). By 
e17.5, the hormone-expressing cell types are present (Japón et al., 1994) and are 
concentrated in distinct regions. In the adult gland the anterior pituitary cells are more 
mixed. 
1.3 Signaling Molecules in Early Pituitary Development 
Gradients of protein signaling molecules between the oral ectoderm and ventral 
diencephalon are important for formation of Rathke’s pouch and the subsequent 
differentiation of the hormone-secreting cells in early pituitary development (Figure 1.1) 
[e.g. (Daikoku et al., 1982; Watanabe, 1982a; Watanabe, 1982b; Kawamura and 
Kikuyama, 1995; Gleiberman et al., 1999)]. Signaling molecules such bone 
morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), sonic hedgehog 
(SHH), Notch, and Wnt (wingless/integrated) are important for the development of a 
diverse array of mammalian organs including the pituitary gland (Figure 1.1).   
BMP signaling is critical for the development and patterning of the mouse 
pituitary from the initial induction of Rathke’s pouch to cell specification in the anterior 
lobe (Ericson et al., 1998; Davis and Camper, 2007). The earliest characterized secreted 
molecule from the prospective infundibulum is BMP4. The initial step of Rathke’s pouch 
formation requires invagination of the oral ectoderm and this process is BMP4-
dependent. The highest expression level of BMP4 is at e9.5 and it stays on until Rathke’s 
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pouch is fully formed (Ericson et al., 1998). Bmp4 null mice display no formation of the 
Rathke’s pouch placode (Takuma et al., 1998). 
Fibroblast growth factors (FGFs) are a family of signaling proteins involved in 
many aspects of embryonic development such as angiogenesis [reviewed in (Cross and 
Claesson-Welsh, 2001)]. FGFs are important for organogenesis and cell differentiation in 
the developing pituitary gland. FGF8, 10, and 18 have been found in the ventral 
diencephalon and posterior pituitary in mice after initial induction by BMP4 (Treier et al., 
1998; Treier et al., 2001). In mice lacking either Fgf10 or FGF receptor 2, Rathke’s 
pouch forms but undergoes apoptosis at e14.5 (Ohuchi et al., 2000). This suggests that 
Fgf10 is essential for pituitary cell survival (Sun et al., 1999; Revest et al., 2001).    
SHH has an important role in delineating the area for Rathke’s pouch formation 
and it is expressed in both in the ventral diencephalon and throughout the oral ectoderm 
(Treier et al., 2001). The effect of loss of Shh in mice on pituitary development disrupts 
diencephalon formation at an early embryonic stage. Pituitary-specific blockage of SHH 
signaling by the SHH antagonist HIP prevents Rathke’s pouch formation, and 
experimental over-expression of SHH in the developing pituitary of mice resulted in 
pituitary hyperplasia (Treier et al., 2001).  
Wnt/β-catenin pathway signaling is important for controlling proliferation of cell 
types and stem cell fate during development. Wnts are highly expressed between e11.5 
and e15.5 in mouse pituitary development and are required for pituitary cell 
determination and pituitary gland growth, especially for the pituitary specific 
transcription factor-1 (PIT-1)-dependent cell lineages (thyrotropes, somatotropes, and 
lactotropes). Several studies support roles for Wnt/β-catenin signaling in pituitary 
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development. For example, β-catenin can regulate the activity of two transcription factors 
with roles in pituitary development: pituitary homeobox 2 (PITX2), and steroidogenic 
factor 1 (SF1) (Kioussi et al., 2002; Brinkmeier et al., 2003; Gummow et al., 2003). Ten 
of the 19 Wnt genes are detected in the developing pituitary (Olson et al., 2006). Wnt4 
and Wnt5 have been reported to be specifically associated with the developing events of 
the anterior pituitary. Wnt5 is expressed in the ventral diencephalon and deletion of this 
gene causes extra bifurcations of Rathke’s pouch (Cha et al., 2004). Wnt4-/- mice have 
anterior hypoplasia with reduced number of gonadotropes, thyrotropes, and somatotropes 
(Treier et al., 1998). Wnt5
-/-
 mice have an enlarged intermediate lobe and an increased 
number of POMC cells in the anterior and intermediate lobe (Cha et al., 2004).  
1.4 Transcription Factors in Anterior Pituitary Development 
During embryogenesis, important signaling molecules (as described above) and 
transcription factors including PITX1, PITX2, PIT-1, PROP1, TPIT, SF1, GATA2, ISL1, 
LHX4, and LHX3 and important in guiding the anterior pituitary development (Figure 
1.1). These factors have been shown to play important roles in anterior pituitary lineage 
specification and differentiation (Figure 1.1) (Hashimoto et al., 2005; Kelberman et al., 
2009; Davis et al., 2010; Mollard et al., 2012). For example, the PIT-1 homeodomain 
transcription factor is required for development of the GH-, TSH-, and PRL-expressing 
cells; and steroidogenic factor 1 (SF1) and GATA2 play roles in gonadotrope cell 
differentiation (Ingraham et al., 1988; Li et al., 1990; Ingraham et al., 1994; Dasen et al., 
1999).  
  
  7 
PITX1 
The pituitary homeobox (Pitx) family contains three bicoid-related homeobox 
genes (Pitx1, 2, 3) and each gene has roles in development (Gage et al., 1996b). The 
PITX1 and PITX2 proteins are best characterized in pituitary development. PITX1 was 
discovered as a protein interaction partner of the pituitary specific transcription factor 1, 
PIT-1 (Szeto et al., 1999). PITX1 was also identified as an activator of the POMC gene in 
corticotropes (Lamonerie et al., 1996). PITX1 and PITX2 expression initiates at e8 in the 
tissue that gives rise to Rathke’s pouch and expression persists through adulthood (Suh et 
al., 2002). Both factors can bind to the promoters of pituitary-expressed genes such as 
αGSU, TSHβ, LHβ, FSHβ, PRL, and GH and may be involved in transcription of these 
genes in hormone-secreting cells (Tremblay et al., 2000). PITX1 activation is required for 
the later actions of other transcription factors including PIT-1 (Tremblay et al., 1998). In 
vitro PITX1 knockdown experiments show a lack of αGSU and LHX3 expression in 
PITX1 knockdown cell lines (Tremblay et al., 1998) and similar results were 
recapitulated in vivo (Charles et al., 2005). These data suggest that PITX1 acts as an 
upstream regulator of LHX3 in the pituitary development signal cascade (Figure 1.1). 
Pitx1
-/-
 mice form a normal Rathke’s pouch, however the number of gonadotrope and 
thyrotrope cells is reduced. Also there is abnormal high expression of ACTH at e17.5 
(Szeto et al., 1999), and hindlimb and cleft plate development defects are reported 
(Lanctot et al., 1999; Szeto et al., 1999).  
PITX2 
Pitx2 is also implicated in early pituitary development. With expression in 
developing pituitary, eye, and brain, PITX2 is proposed to have roles in the proper 
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development and maintenance of anterior structures. The PITX2 gene was initially 
identified as the gene responsible for Rieger syndrome in humans and the symptoms 
include abnormalities in eye, tooth, brain, heart, and anterior pituitary with some patients 
displaying GH deficiency (Semina et al., 1996) (Semina et al., 1996; Gage and Camper, 
1997). Mice with deficiency of the Pitx2
 
gene have abnormal left-right asymmetry; 
developmental defects in heart, lung, eye, tooth, and abnormalities in the proliferation 
and differentiation of pituitary cells leading to hypoplastic pituitary structures (Semina et 
al., 1996; Logan et al., 1998; Piedra et al., 1998; Ryan et al., 1998; Yoshioka et al., 1998; 
Lin et al., 1999; Lu et al., 1999; Suh et al., 2002). In these mice, invagination of Rathke’s 
pouch occurs normally, however, the gland becomes “frozen” at e10.5 and contains few 
corticotropes. Furthermore, no PIT-1 induction occurs and TSH, GH, PRL cells are 
missing. There is low expression of the PROP1 homeodomain protein in Pitx2
-/-
 mice 
suggesting that PITX2 is a regulator of pituitary development upstream of PROP1 
(Figure 1.1) and necessary for hormone-expressing lineage precursor expansion (Suh et 
al., 2002).   
PIT-1 
The POU-homeodomain family of transcription factors are named from the three 
“founding” transcription factors, the pituitary-specific Pit-1, the octamer-binding proteins 
Oct-1/2, and the neural Unc-86. PIT-1 is a lineage-specific transcription factor and was 
the first pituitary specific transcription factor to be identified (Bodner et al., 1988; 
Ingraham et al., 1988). Expression of Pit-1 is restricted to the caudomedial region of the 
developing pituitary gland and PIT-1 activates pituitary genes such as the GH, GH-
releasing hormone receptor (GHRHR), PRL, TSHβ and genes and its own gene via 
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autoregulation [e.g. (Li et al., 1990; Rhodes et al., 1993)]. Mutations in the mouse Pit-1 
gene underlie the phenotypes of the Snell and Jackson dwarf mouse models which lack 
GH, PRL, and TSH, providing evidence for an essential role of PIT-1 in determination of 
pituitary somatotropes, lactotropes, and thyrotropes (Li et al., 1990). Studies using the 
Snell mice reveal that thyrotropes may be derived from two distinct cell populations; 
PIT-1 dependent lineages are located in the caudomedial portion of the gland and these 
TSH-expressing cells persist into adulthood. In contrast, PIT-1-independent thyrotropes 
are located in the rostral tip region, and these cells are only seen in early pituitary 
development (Lin et al., 1994). Rostral tip thyrotropes start to appear at ~e12.5 and PIT-1 
dependent thyrotropes arise at ~e14.5 during pituitary development. Consistent with the 
Pit-1-disrupted mouse phenotypes, humans with mutations in the PIT-1 gene (also known 
as the POU1F1 gene in humans) have hypothyroidism, dwarfism, and deficiency of the 
PRL, GH, and TSH hormones (Figure 1.1) (Ohta et al., 1992; Pfaffle et al., 1992; 
Radovick et al., 1992). 
PROP1 
A paired-class homeodomain gene, the Prophet of Pit-1 (Prop1) gene, is 
expressed in the developing anterior pituitary gland at ~e10.5 until ~e16.5 and is required 
for pituitary organogenesis (Nasonkin et al., 2004; Ward et al., 2005). The mutant Ames 
dwarf mice (Prop1
df/df
) have a missense mutation causing a serine to proline substitution 
in the homeodomain of murine PROP1 and have notable decreases of thyrotropes, 
somatotropes, and lactotropes, similar to the Snell and Jackson mice (Andersen et al., 
1995; Sornson et al., 1996). Pit-1 is effectively absent in Ames mice suggesting that Pit-1 
lies downstream of Prop1 in pituitary development (Tang et al., 1993; Andersen et al., 
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1995; Gage et al., 1995; Gage et al., 1996a; Sornson et al., 1996). Mutations in the 
PROP1 gene are the most common known cause of combined pituitary hormone 
deficiency (CPHD; meaning loss of GH plus one or more other pituitary hormones) (the 
majority of CPHD diseases remain uncharacterized). The clinical features of these 
patients include dwarfism and deficiency of GH, TSH, PRL, LH hormones with common 
onset of ACTH deficiency (Böttner et al., 2004). 
TPIT 
TPIT is T-box class pituitary transcription factor that is expressed in POMC-
producing corticotrope cells of the intermediate and anterior pituitary (Lamolet et al., 
2001). TPIT synergizes with PITX1 to activate the POMC gene in specification of the 
corticotropes of the anterior pituitary (Lamolet et al., 2001; Liu et al., 2001). Mice 
lacking the Tpit gene and pediatric patients with mutations in the human TPIT gene 
display a reduced corticotrope cells in the anterior pituitary (Lamolet et al., 2001; 
Pulichino et al., 2003). Together, these studies suggest that TPIT is important for POMC 
gene transcription and expansion or survival of corticotrope cells in the pituitary gland.  
SF1 
SF1 (steroidogenic factor 1), a nuclear receptor, is necessary for adrenal and 
gonadal development and also is expressed in the ventral diencephalon and in the 
gonadotropes of the developing anterior pituitary gland [reviewed in (Schimmer and 
White, 2010)]. SF1 regulates the hypothalamic-pituitary-gonadal and hypothalamic-
pituitary-adrenal axes (Ikeda et al., 1995). SF1 is first detected at ~e13.5 in the 
developing pituitary and Sf1 gene knockout mice are not viable and have no expression of 
FSH, LH, and the gonadotropin-releasing hormone receptor (GnRHR) (Ingraham et al., 
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1994; Ikeda et al., 1995). Pituitary-specific Sf1 knockout mice are viable, but sexually 
immature with no expression of FSH and LH. The male mice exhibit hypoplasia of the 
gonads and reduction of Leydig cells. In female mice, development of ovaries occurs 
normally but pre-ovulatory follicles are not produced (Zhao et al., 2001). Mouse model 
studies suggest that SF1 is involved in the differentiation of the gonadotrope lineages and 
directly regulates LH and FSH expression.  
GATA transcription factors 
Normal reproduction depends on proper development and function of the 
hypothalamic-gonadotrope-gonadal axis. The GATA transcription factor family is well 
characterized as a regulator of gene expression in hematopoietic cells (Orkin, 1992), and 
they also play important roles in reproduction (LaVoie, 2003; Viger et al., 2008). In 
vertebrates, the GATA family is composed of six members. GATA1/2/3 play roles in 
hematopoietic and nervous system development (Ohneda and Yamamoto, 2002; Patient 
and McGhee, 2002), and GATA4/5/6 factors are involved in development of organs 
including the heart, gut, and vasculature (Morrisey et al., 1996; Molkentin, 2000; 
Molkentin et al., 2000). GATA members have highly conserved protein sequences in 
their zinc finger DNA binding domains and GATA factors bind to a consensus binding 
motif (A/T)GATA(A/G) in DNA (Merika and Orkin, 1993; Lowry and Atchley, 2000). 
GATA2 and GATA3 play roles in blood and nervous system development but 
also are expressed in the developing anterior pituitary (Dasen et al., 1999; Suh et al., 
2002). Both of mRNAs are found at ~e10.5 and GATA2 expression persists into the adult 
(Dasen et al., 1999). GATA2 has been shown to be involved in the differentiation of 
gonadotrope and thyrotrope cell lineage through the interactions with PIT-1 in the 
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developing pituitary (Dasen et al., 1999; Suh et al., 2002). GATA2-expressing cells 
include gonadotropes and PIT-1 dependent thyrotropes (Dasen et al., 1999). GATA2 also 
has been proposed to activate the expression of SF1 (Steger et al., 1994), which in turn 
stimulates αGSU and LHβ gene expression, however, GATA2 may not influence FSHβ 
expression (Brown and McNeilly, 1999). In vitro analysis reveals that GATA2 can 
activate transcriptional activity of the LHβ gene promoter by interacting with SF1 (Lo et 
al., 2011). Studies have shown that GATA2 colocalizes with αGSU pituitary lineages, the 
thyrotropes and gonadotropes. Gata2 null homozygous embryos die at e11.5 due to 
severe anemia (Tsai et al., 1992). Pituitary-specific Gata2 knockout mice display 
reduction of gonadotropes and thyrotropes in neonates (Charles et al., 2006). Recently, 
mutations were identified within the human GATA2 gene and the majority of these 
patients have primary lymphedema (Ishida et al., 2012; Kazenwadel et al., 2012).  
1.5 LIM-Homeodomain Transcription Factors, ISL1, LHX4 and LHX3 
 The LIM domain nomenclature is derived from the first letters of the names of the 
founding members: LIN11, ISL1, and MEC3 (Bach, 2000; Hunter and Rhodes, 2005). 
The LIM domain is a zinc-coordinated protein-protein interaction domain. The LIM 
family includes transcription factors, cytoskeletal proteins, signaling proteins, and 
transcriptional co-activators [reviewed in(Bach, 2000)]. LIM-homeodomain (LIM-HD) 
transcription factors have two LIM domains located in the amino terminus that are 
involved in protein-protein interactions, and a central homeodomain involved in DNA 
binding [reviewed in (Hunter and Rhodes, 2005; Prince et al., 2011)]. Members of the 
LIM-HD transcription factor family, including ISL1, LHX3, and LHX4, have important 
roles in pituitary and nervous system development [reviewed in (Prince et al., 2011)]. 
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ISL1 
LIM-HD transcription factor Islet1 (ISL1) was first found insulin-producing cells 
in the pancreas and it is able to bind to the insulin gene enhancer (Karlsson et al., 1990). 
Isl1 is expressed in multiple organs including pancreas, pituitary, thyroid, kidney, spinal 
cord, diencephalon, telencephalon, inner ear, and heart (Karlsson et al., 1990; Dong et al., 
1991; Thor et al., 1991; Cai et al., 2003; Mitsiadis et al., 2003; Radde-Gallwitz et al., 
2004). Isl1 is an early expressed transcription factor during pituitary development and 
can be detected at ~e8.5 in the oral ectoderm (Pfaff et al., 1996; Ericson et al., 1998). 
Dorsal-ventral patterning involving gradients of signaling molecules including BMP2 and 
FGF8/FGF2 appear to control the expression of Isl1 during pituitary development 
(Ericson et al., 1998). Recently, studies have shown that ISL1 activates FSHβ and LHβ 
gene expression in response to leptin (Wu et al., 2010).  
Lack of the Isl1 gene in the mouse is embryonic lethal at approximately at ~e10.5 
due to developmental defects in the pancreas, heart, pituitary, and nervous system. Isl1
-/- 
mice form a primitive pouch at e9.5 with a thin epithelium layer, but then development 
arrests (Takuma et al., 1998). Isl1 knockout mice have no LHX3 expression in the 
pituitary but ISL1 expression is present in Lhx3 null mice at e9.5. However, ISL1 
expression in Lhx3 null
 
mice is transient in that there is no ISL1 expression at e12.5 and 
after this time point ISL1 expression returns (Ellsworth et al., 2008). These results 
suggest that ISL1 is upstream of LHX3 expression and that Lhx3 is required for 
maintaining ISL1 expression at certain period of time in the developing pituitary.  
ISL1 is a motor neuron (MN) marker in MN specification in the developing 
nervous system. Using the chicken models system, ISL1 has been shown to work with 
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other LIM-HD factors and signaling molecules to specify MN subtypes in the developing 
nervous system [reviewed in (Liang et al., 2011)]. For example, the signaling molecule 
SHH activates ISL1 and LHX3 expression, and ISL1 and LHX3 expression are required 
for proper MN differentiation and specification (Lee and Pfaff, 2001). In order to specify 
MNs, ISL1 and LHX3 form a MN hexamer complex which includes NLI (nuclear LIM 
domain interactor), and the NeuroM and E47 basic-helix-loop-helix (bHLH) transcription 
factors (Thaler et al., 2002; Lee et al., 2008). MNs can be defined by expression of ISL1 
and the homeobox 9 (Hb9) transcription factor, and these are the some of the first 
detected MN genes expressed in the ventral area of post-mitotic neurons in spinal cord 
(Pfaff et al., 1996; Saha et al., 1997; Tanabe et al., 1998). Isl1
-/-
 embryos lack MNs and a 
subpopulation of interneurons (Pfaff et al., 1996).  
LHX4 
LHX4 is another member of the LIM-HD transcription factor family. LHX3 and 
LHX4 are structurally similar, sharing 63% overall amino acid identity, with 75~95% 
homology in the LIM domains and the homeodomain [reviewed in (Mullen et al., 2007)]. 
LHX4 and LHX3 have overlapping functions in pituitary development and MN 
specification (Sheng et al., 1996; Sheng et al., 1997; Sharma et al., 1998). LHX4 can bind 
to pituitary target gene promoters and enhancers including the αGSU, GH, PRL, FSHβ, 
and PIT-1 genes, and activate their expression [e.g. (Sloop et al., 2001; Kawamata et al., 
2002; West et al., 2004; Machinis and Amselem, 2005; Castinetti et al., 2008)].  
In mice, Lhx4 is expressed in the developing pituitary gland, hindbrain, cerebral 
cortex, and spinal cord (Li et al., 1994; Liu et al., 2002). Lhx4 expression in the pituitary 
begins at e9.5 and its expression is restricted in the primordium of anterior lobe and by 
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e12.5 coincides with Lhx3 (Sheng et al., 1997). Mice lacking Lhx4 form Rathke’s pouch 
normally but fail to expand and fully differentiate hormone-secreting cells. These mice 
die shortly after birth due to a defect in lung development (Li et al., 1994). However, 
heterozygous Lhx4 mutant mice are apparently normal. The development of the pituitary 
in the Lhx3 and Lhx4 double knockout mice arrests at a rudimentary pouch development 
stage, whereas single mutant mice form a definitive pouch (Sheng et al., 1997). Further 
studies suggest that Lhx4 action with Prop1 is necessary for proper function of Lhx3 and 
pituitary hormone-secreting cell expansion (Raetzman et al., 2002). Although LHX4 is 
structurally and functionally similar to the LHX3 gene, the clinical features of patients 
with LHX4 gene mutations are somewhat different than those of LHX3 patients (Prince et 
al., 2011). All LHX4 patients characterized to date have heterozygous mutations and 
CPHD. They commonly lack GH and TSH, but lack of LH, FSH, PRL, and ACTH is 
variable (Machinis et al., 2001; Tajima et al., 2007; Castinetti et al., 2008; Pfaeffle et al., 
2008; Dateki et al., 2010). Other clinical symptoms of mutations in LHX4 can include 
hypoplasia or hyperplasia of the anterior pituitary, ectopic posterior pituitary glands, sella 
turcica abnormalities, and brain malformations (Machinis et al., 2001; Tajima et al., 2007; 
Castinetti et al., 2008; Pfaeffle et al., 2008; Dateki et al., 2010).  
LHX3 
The human LHX3 gene contains seven exons and six introns and is located on 
chromosome 9q34 (Sloop et al., 2000a; Sloop et al., 2000b). Mammalian LHX3 genes 
produce two mRNAs known as LHX3a and LHX3b from alternative splicing of exon Ia 
and exon Ib, and these mRNAs encode three protein isoforms, LHX3a, LHX3b, and M2-
LHX3. LHX3a and LHX3b both contain the two LIM domains and DNA-binding 
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homeodomain but have alternate amino termini (Figure 1.2) (Sloop et al., 1999; Sloop et 
al., 2001; Yaden et al., 2006). M2-LHX3, a truncated form of the protein, has no LIM 
domains in the amino terminus, but has a homeodomain and a trans-activation domain 
(Sloop et al., 2001). The human LHX3 gene has two proximal promoters (LHX3a and 
LHX3b) that are located upstream of exon Ia and exon Ib respectively: these promoters 
guide production of the LHX3a and LHX3b mRNAs. Both promoters have GC-rich 
regions and lack a true TATA box. Transcriptional regulation at the human LHX3 
promoters involves binding of specificity protein 1 (SP1) and nuclear factor 1 (NF1) 
(Yaden et al., 2006). Recently, we demonstrated that the two promoters are not sufficient 
to guide LHX3 gene expression in vivo (Mullen et al., 2012). In the human LHX3 gene, a 
7.9 kilobase (kb) 3'-located enhancer containing potential binding sites for PITX1 and 
ISL1 can guide pituitary and spinal cord gene expression (Mullen et al., 2012).  
The LHX3 protein is expressed in the developing and mature pituitary gland, the 
neurons of the developing spinal cord and hindbrain, the retina, and the pineal gland 
(Zhadanov et al., 1995; Sheng et al., 1996; Sharma et al., 1998; Sloop et al., 2000a; Sloop 
et al., 2000b). The importance of LHX3 during pituitary development was elucidated in 
Lhx3 knockout mice models. In mice, Lhx3 expression begins at about e9.5 in Rathke’s 
pouch and persists in the anterior and intermediate lobes of the adult pituitary. Lhx3
 
null 
mice are born but die within ~24 hours of birth (Sheng et al., 1996). In these mice, the 
pituitary gland is arrested after formation of a definitive Rathke’s pouch, however the 
posterior and intermediate lobes develop normally. Heterozygous Lhx3
+/-
 mice are viable 
and all of the hormone-producing cells are present in the anterior pituitary (Sheng et al., 
1996). In the Lhx3 null mice, the somatotropes, thyrotropes, lactotropes, and 
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gonadotropes fail to differentiate and proliferate, and only a few corticotropes are present 
(Sheng et al., 1996; Sheng et al., 1997). Neither the early pituitary-expressing Hesx1 gene 
or the pituitary cell lineage-specific Pit-1 gene are detectable in Lhx3 null mice (Sheng et 
al., 1996). A study using mice (Lhx3
Cre/Cre
) generated with an insertion of 3' untranslated 
region (UTR) into the Lhx3 gene reveals that reduced levels of LHX3 cause a similar 
phenotype to Lhx3 null mice. In these mice with reduced LHX3 level there is increased 
cell apoptosis (Zhao et al., 2006); similarly, high apoptosis is noted in Pitx1 null mice 
which lack LHX3 expression (Charles et al., 2005). These data suggest a threshold level 
of LHX3 is important for proper pituitary development.  
LHX3 has additional roles in differentiation of MNs and V2 interneurons (INs) 
(Pfaff et al., 1996; Glasgow et al., 1997; Sharma et al., 1998; Thor et al., 1999; Thaler et 
al., 2002). The V2 INs are derived from a common progenitor population expressing 
LHX3 (Peng et al., 2007), and are subdivided into two classes V2a INs: those that 
express the CHX10 homeodomain transcription factor, and V2b INs that express GATA2 
and GATA3 (Ericson et al., 1997; Zhou et al., 2000; Karunaratne et al., 2002; Smith et 
al., 2002). For V2 IN specification, LHX3 is proposed to form a tetrameric complex 
comprised of two LHX3 proteins and 2 copies of NLI. A hexameric MN protein complex 
is needed for MN specification as described above (Thaler et al., 2002; Lee et al., 2008).  
Coding region mutations in pituitary transcription factor genes including PROP1, 
PIT-1, PITX2, LHX3 and LHX4 have been indicated in cases of CPHD [e.g. (Pfaffle et 
al., 1992; Dattani et al., 1998; Wu et al., 1998; Netchine et al., 2000; Brickman et al., 
2001; Lamolet et al., 2001; Machinis et al., 2001; Thomas et al., 2001; Pfaeffle et al., 
2007)]. However genetic defects have not been characterized in most CPHD patients yet. 
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Twelve homozygous mutations have been found in the coding regions of the human 
LHX3 gene that result in CPHD (Table 1.1). Most of the patients carrying LHX3 
mutations have a rigid cervical spine and this may due to the role of LHX3 in 
specification of neuronal cells in the developing spinal cord. One family has a W224Ter 
LHX3 mutation and CPHD but not the limited neck rotation (Pfaeffle et al., 2007). This 
mutation is found in four siblings from a consanguineous Lebanese couple. This 
substitution introduces a premature stop codon predicted to cause loss of the carboxyl 
terminus of the LHX3 protein (W224Ter) (Pfaeffle et al., 2007). An animal model 
mimicking the human LHX3 W224Ter mutation reveals that these mice are viable, but 
have reduced levels of PRL and TSH. Female homozygous mice display infertility but 
there are no obvious nervous system defects (Colvin et al., 2011).  
Most LHX3 patients are deficient in GH, TSH, LH, FSH, PRL and some cases are 
reported to be ACTH-deficient. These LHX3 patients survive, but have short stature, 
hypothyroidism and hypogonadism (Netchine et al., 2000; Machinis et al., 2001; 
Bhangoo et al., 2006; Rajab et al., 2008; Kristrom et al., 2009). Recently, studies from 
our group and a collaborator have shown that a novel homozygous mutation causing a 
threonine to arginine substitution at position 194 (T194R) in the LHX3 homeodomain 
causes CPHD (Bechtold-Dalla Pozza et al., 2012). This patient has a hypoplastic anterior 
pituitary and a rigid cervical spine (Figure 1.3). Sequence alignment of human the LHX3 
protein amino acid sequence with multiple other species reveals that the threonine at 
position 194 is conserved in all LHX3/LIM3 proteins. In a 3-dimensional computational 
model predicted for the wild type LHX3 protein, T194 is located at the end of the second 
alpha-helix of the homeodomain (Figure 1.3), and it likely contributes to stabilize the 
  19 
tertiary structure by establishing a predicted hydrogen bond with a glutamine (Q170) 
residue (Figure 1.3. B). When T194 is changed to arginine, this mutation may cause steric 
hindrance with leucine (L172) (Figure 1.3. C). This steric hindrance may destabilize the 
helix-turn-helix tertiary structure. To test whether this might affect DNA binding, I 
performed electrophoretic mobility shift analyses (EMSA) using wild type LHX3 protein 
and T194R LHX3 protein. The T194R “mutant” protein could not bind to a LHX3 
consensus-binding site (Figure 1.5. A). Further, to examine the ability of the T194R 
LHX3 protein to activate pituitary genes, LHX3 expression vectors were co-transfected 
with a prolactin (PRL) promoter reporter gene into pituitary GHFT1 cells. Wild type 
LHX3 activated the PRL promoter, but T194R LHX3 was not activated (Figure 1.5. B). 
These clinical and molecular studies suggest that a novel homozygous T194R LHX3 
mutation alters the molecular properties of LHX3 homeodomain and this mutation causes 
CPHD.   
1.7 Central Hypothesis and Aims 
Our lab previously identified two promoters/intronic elements of the human LHX3 
gene that are important for basal gene expression in vitro (Yaden et al., 2006), but the 
mechanisms by which the LHX3 gene is regulated in vivo were not known. Beta 
galactosidase reporter transgenic mouse models were used to examine whether the LHX3 
promoters are able to drive a reporter transgene in vivo. However, the LHX3 promoters 
were not able to drive beta galactosidase expression in any tissues, including the pituitary 
and spinal cord (Figure 1.6.) (Mullen et al., 2012). This suggested to us that elements 
outside of the promoter region are necessary to guide LHX3 gene expression. Using the 
bioinformatics VISTA program (Bray et al., 2003; Couronne et al., 2003), we found 
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highly conserved non-coding elements, which are often associated with regulatory 
function, within the 7.9 kb region 3′ of the human LHX3 gene (Figure 1.7. A). The 
addition of this 7.9 kb region 3′ from the LHX3 gene to the native promoter beta 
galactosidase transgenic reporter gene resulted in tissue-specific beta galactosidase 
expression in the developing pituitary and spinal cord of the transgenic mice (Figure 1.7. 
B) (Mullen et al., 2012). This result demonstrated that the 7.9 kb region 3′ of the LHX3 
gene can mediate reporter gene expression in vivo and suggests that this element is 
important for human LHX3 gene expression. To further test enhancer activity, we used a 
heterologous HSP68 minimal promoter which does not alone direct gene expression 
without additional enhancers (Kothary et al., 1989; Pennacchio et al., 2006). One of the 
characteristics of an enhancer is the ability to act independent of position to direct 
expression from a basal promoter. In the HSP68 minimal promoter system, the 7.9 kb 
conserved enhancer region directed tissue-specific expression to the pituitary gland and 
spinal cord of transgenic mice independent of its “normal” position (Figure 1.7. B) 
(Mullen et al., 2012). The observed enhancer-directed transgene expression (beta 
galactosidase activity) matched endogenous LHX3 expression in the developing pituitary 
and spinal cord (Figure 1.8).  
Within the enhancer, several transferable cis elements can individually guide 
nervous system expression in vivo; however, a 180 base pair (bp) minimal enhancer is 
alone sufficient to confer specific expression in the developing pituitary (Mullen et al., 
2012). Within this sequence, ISL1 protein binds to A/T rich homeodomain binding sites 
and these sites are necessary for 3′ enhancer activity in the developing pituitary gland and 
the spinal cord. Also a putative PITX1 homeodomain element may be required for spatial 
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patterning of LHX3 expression in the developing pituitary. This study suggested a 
mechanism for ISL1 transcriptional regulation of the human LHX3 gene and described a 
potential mechanism for regulation by PITX1 (Mullen et al., 2012).  
Our previous study (Mullen et al., 2012) did not characterize human LHX3 gene 
3′ enhancer-directed transgene expression on a cellular level. The hypothesis for my 
study was that the 3′ enhancer has roles in LHX3 expression during the development of 
the hormone-expressing cell types of the anterior pituitary. This hypothesis was based on 
the following observations. LHX3 has critical roles in the development of the anterior 
pituitary hormone-secreting cell types includes somatotropes, lactotropes, thyrotropes, 
and gonadotropes. Human patients with LHX3 mutations (Table 1.1) and Lhx3 knockout 
mice have TSH, LH, FSH, GH deficiencies [reviewed in (Prince et al., 2011)]. In this 
study, we investigated the role of this distal regulatory region in the control of regulating 
LHX3 gene expression at a cellular level during development.  
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Figure 1.1. Regulation of the development of anterior pituitary gland hormone-expressing 
cells by signaling molecules and transcription factors. Inductive signaling events between 
the ventral diencephalon (DIEN) and the oral ectoderm (OE) precede the formation of a 
rudimentary Rathke’s pouch that eventually forms a definitive closed Rathke’s pouch, 
and then the mature anterior pituitary. Multiple transcription factors are involved in the 
determination and differentiation of the five different hormone-secreting cell types. The 
time points of appearances of the hormone-secreting cells during mouse embryogenesis 
are noted. FSH, LH, and TSH are heterodimers sharing a common alpha glycoprotein 
subunit (αGSU). 
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Figure 1.2. The human LHX3 gene spans approximately 8.7 kb of sequence and contains 
seven exons (roman numerals) and six introns (arabic numerals). Exons are depicted by 
boxes and introns are indicated by lines. This gene produces two major mRNAs (LHX3a 
and LHX3b) encodes three LHX3 protein isoforms (LHX3a, LHX3b, M2-LHX3). The 
M2-LHX3 isoform has the homeodomain region but lacks the LIM domains. Modified 
from (Sloop et al., 1999).   
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Figure 1.3. DNA analysis reveals a novel homozygous mutation (T194R) in the LHX3 
gene in patients with CPHD. A, pedigree of the affected family. Filled symbols indicate 
patients with homozygous genotype. Half-filled symbols denote heterozygous 
individuals. A line through a symbol indicates that the subject is deceased. The dotted 
line indicates a family connection four or five generations back from the index patient 
(IV4). B, MRI pictures show patient IV4 has a hypoplastic anterior pituitary gland and 
rigid cervical spine. The anterior pituitary is hypoplastic (open arrow) and unaffected the 
posterior pituitary gland is found in the expected location (arrow). C, DNA sequencing 
analysis of patient IV4 reveals a C to G mutation in the LHX3 gene altering a threonine 
(Thr) to an arginine (Arg) in the predicted homeodomain amino acid sequence. Adapted 
from (Bechtold-Dalla Pozza et al., 2012).  
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Figure 1.4. Structural prediction of LHX3 homeodomain/DNA interaction. A, Ribbon 
model of WT LHX3 homeodomain/DNA showing the three α-helices in orange (helix 1), 
green (helix 2) and purple (helix 3). B, Predicted WT LHX3 homeodomain with a 
threonine at position 194 (Thr194). C, Predicted T194R LHX3 homeodomain with an 
arginine at position 194 (Arg194). The figure shows R194 position(green side chains) 
that may destabilize the tertiary structure by causing steric hindrance (purple dotted lines) 
with glutamine 170 and leucine 192 (orange side chains). Adapted from (Bechtold-Dalla 
Pozza et al., 2012).  
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Figure 1.5. The LHX3 T194R protein does not bind to LHX3 DNA recognition elements 
and is not able to activate a pituitary target gene. A, EMSA experiments were performed 
using the WT LHX3 or T194R LHX3 proteins translated in vitro in rabbit reticulocyte 
lysates and radiolabeled probes representing the LHX3 consensus-binding site (Bridwell 
et al., 2001). Unprogrammed lysates were used as negative controls (Control). The 
LHX3/DNA complexes are denoted by an arrowhead. B, Expression vectors for WT 
LHX3 and T194R LHX3 proteins were transiently cotransfected into mouse pituitary 
GHFT1 cells with a luciferase reporter gene under the control of the prolactin (PRL) 
promoter. Promoter activity was assayed by measuring luciferase activity 48 h after 
transfection. Negative controls (Control) received equivalent amounts of empty 
expression vector plasmid. Activities are mean (light units/10 s/μg total protein) of 
triplicate assays ± SEM. A representative experiment of at least three experiments is 
depicted. F, Free probe. Modified from (Bechtold-Dalla Pozza et al., 2012).  
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Figure 1.6. Two basal promoters of the human LHX3 gene are not sufficient to drive 
transgene (LacZ) activity in vivo. Reporter gene constructs with hLHX3a promoter, intron 
Ia/hLHX3b promoter, or the hLHX3a promoter and intron Ia/hLHX3b promoter together 
used to generate transgenic mice. Sagittal cryosections of e14.5 embryos stained for beta 
galactosidase activity. There is no beta galactosidase expression in the pituitary or spinal 
cord. P, posterior lobe; I, intermediate lobe; A, anterior lobe. Adapted from (Mullen et 
al., 2012). 
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Figure 1.7. A conserved distal downstream region (~7.9 kb) of the human LHX3 gene can 
direct expression to the developing pituitary and spinal cord in vivo. A. Comparative 
genomic analysis of the human LHX3 gene using ECR browser. LHX3 gene sequence 
alignments in multiple species revealed that non-coding elements (CNE) in the 3′ region 
of the human LHX3 gene. CNE are shown in red, coding exons in blue, conserved 
intronic regions in salmon, UTR in yellow, and simple repeats in green. B, reporter gene 
containing the 7.9 kb 3′ region guide transgene expression in the developing pituitary and 
spinal cord. Sagittal frozen mouse pituitary and spinal cord sections of e14.5 founder 
embryos stained for beta galactosidase activity. Modified from (Mullen et al., 2012).  
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Figure 1.8. 7.9 kb 3′ enhancer-directed transgene expression coincides with native LHX3 
expression. Frozen pituitaries and spinal cord sections from the human LHX3 7.9 kb 
enhancer-LacZ mice at e9.5 were stained for LHX3 expression using antibodies (green) 
or beta galactosidase transgene activity (blue). RP, Rathke’s pouch; SC, spinal cord. 
Adapted from (Mullen et al., 2012). 
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Table 1.1 Mutations within the LHX3 gene associated with combined pituitary 
hormone deficiency disease. Adapted from (Bechtold-Dalla Pozza et al., 2012). 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 DNA Cloning and Vector Construction  
3′ Enhancer pSC-B Construct 
To construct the 7.9 kb 3′ enhancer pSC-B cloning vector, two sets of primers 
were used to amplify 7.9 kb 3 human LHX3 enhancer from 700 ng of BAC clone RP11-
83B9/ALI38781 using Pfu Ultra II HS DNA polymerase (Stratagene, La Jolla, CA). The 
following primers: 5′-cgggatccgacccagttcgacctatcc-3′ (S) and 5′-
gaacagtcggcacttattaaccacctgtcagc-3′ (AS) for fragment I; 5′-ccaggtcgaaggcggaattagggag-
3′ (S) and 5′-acgcgtcgaccactggcgacatcatctctg-3′ (AS) for fragment II were used. PCR 
parameters were 95°C 2min; 95°C 20 sec, 65°C 20 sec, 72°C 1 min 15 sec for 25 cycles, 
72°C 5 min. PCR products were sub-cloned into pSC-B vector (Stratagene). Inserted 
fragment I and II-pSC-B were digested with NotI and ligated together to form the 3 
enhancer pSC-B vector.   
3′ Enhancer-HSP68 promoter pSC-B transgene  
The HSP68-Hand2-LacZ pSK-Bluescript (a gift from Dr. Simon Conway, Indiana 
School of Medicine, Indianapolis, IN) vector was modified to delete the Hand2 enhancer. 
Next, the HSP68-LacZ sequence was excised from HSP68-LacZ pSK-Bluescript and 
ligated into the 3′ enhancer pSC-B plasmid to make the 3 enhancer- HSP68-LacZ pSC-B 
construct (construction by Rachel Mullen).   
3′ Enhancer-HSP68-Cre transgene (ELHX3Cre) 
To create the human LHX3 gene 3′ enhancer-HSP68-Cre (ELHX3Cre) transgene, 
the 7.9 kb enhancer fragment, and the 920 bp HSP68 minimal promoter were removed 
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from the 3′ LHX3 enhancer-HSP68-LacZ construct and were subcloned into the pBS594-
EGFP-Cre expression vector (Le et al., 1999) using BamHI and NcoI restriction sites 
(Figure 2.1). The pBS594-EGFP-Cre vector was obtained as a generous gift from Dr. 
Simon Conway, Indiana School of Medicine, Indianapolis, IN.   
DNA sequencing 
DNA sequencing was performed at the Biochemistry Biotechnology facility at the 
Indiana School of Medicine using a Perkin Elmer DNA sequencer. The templates for 
sample DNA were submitted using the recommended guidelines from the sequencing 
facility. The sequence analyses and alignments were completed with the DNASIS 
(Hitachi Software Engineering, San Francisco, CA) software. 
2.2 Generation, Genotyping and Breeding of Transgenic Mice 
Generation of transgenic mice 
One hundred micrograms of 3 enhancer-HSP68-Cre construct was linearized 
with PacI digestion. Digested transgene DNA was submitted to the Indiana University 
Cancer Center Transgenic and Knock-out Mouse Core (Indianapolis, IN) for gel 
purification and microinjection. The linearized transgenes were microinjected into F2 
zygotes from C3He/FeJ parents at a concentration of approximately 2-3 ng/μl. After 
microinjection, two-cell stage embryos were transferred to 0.5 day pseudopregnant 
females. C3He/FeJ embryos and transferred into pseudopregnant foster mothers. Founder 
transgenic mice were used for breeding as adults for the generation of stable transgenic 
lines.   
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Genotyping of transgenic mice 
Mouse genomic DNA was obtained from mouse tail snips taken between 
postnatal days 14 and 21 using the genomic DNA solution set kit (Gerard Biotech, 
Oxford, OH) to prepare DNA according to the manufacturer’s instructions. Genotyping 
for Cre-expressing transgenic mouse lines was performed using a multiplex PCR 
amplification of the Cre recombinase region and a wild type control region from the 
receptor-associated protein of the synapse (Rapsn) gene (to check for genomic DNA 
integrity). Oligonucleotides primer sequences used for detection of the Cre recombinase 
region and the wild type gene were as follows; 5′-caatgctgtttcactggttatgc-3′ (S) and 5′-
gtacgtgagatatctttaaccctgat-3′ (AS) for Cre detection and 5′-
aggactgggtggcttccaactcccagacac-3′ (S), 5′-agcttctcattgctgcgcgccaggttcagg-3′ (AS) for the 
Rapsn gene. PCR parameters used for genotyping experiments were 2 min at 94°C; 30 
sec at 94°C, 30 sec at 56°C, 30 sec at 72°C for 30 cycles, and 7 min at 72°C. expected 
Cre and wild type Rapsn gene size were approximately 500 bp and 350 bp. 
Genotyping of reporter lines R26R
LacZ
, R26R
YFP 
and R26
DTA
 was determined by 
PCR analysis using mutant and wild type region-specific sequences with the following 
oligonucleotides: 5′-gcgaagagtttgtcctcaacc-3′ (mutant reverse), 5′-aaagtcgctctgagttgttat-3′ 
(common) and 5′-ggagcgggagaaatggatatg-3′ (wild type reverse). The expected mutant and 
wild type PCR product size were 340 bp and 650 bp, respectively. PCR parameters used 
for genotyping experiments were 3 min at 94°C, (30 sec at 94°C, 1 min at 65°C, 1 min at 
72°C) x 35 cycles, and 2 min at 72°C. Homozygous R26
DTA/DTA 
mice
 
were generated from 
male heterozygous and female homozygous mice.   
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Breeding of transgenic mice 
To maintain ELHX3
Cre
 stable transgenic lines, transgenic founder animals and 
their progenies were bred to C3H female mice (Harlan Laboratories, Indianapolis, IN) to 
generate heterozygotes. The morning after copulation, indicated by the presence of a 
vaginal plug, was considered embryonic day 0.5 (e0.5) and the day of birth was postnatal 
day 0 (P0).  
Reporter strains, ROSA26R
LacZ
 (Soriano, 1999) (R26R
LacZ
; 129S-
Gt(ROSA)26Sor
tm1sor
/J, stock number: 003310) and ROSA26
eGFP-DTA
 (Ivanova et al., 
2005) (R26
DTA
; C.129P2(B6)-Gt(ROSA)26Sor
tm1(DTA)Lky
/J, stock number: 009670) mice 
were purchased from Jackson Laboratories (Bar Harbor, Maine). ROSA26R
EYFP
 (Srinivas 
et al., 2001) (R26R
YFP
; B6.129X1-Gt(ROSA)26Sor
tm1(EYFP)Cos
/J, stock number:006148) 
were generously provided by Dr. Paul Herring, Indiana School of Medicine, Indianapolis, 
IN. Mice were housed in a specific pathogen-free environment under controlled 
conditions of temperature and light and were provided free access to tap water and 
commercial mouse chow. The Indiana University Committee on Use and Care of 
Animals approved all procedures using mice, and all experiments were performed in 
agreement with the principles and procedures outlined in the National Institutes of Health 
Guidelines for the Care and Use of Experimental Animals. 
2.3 Histology and Immunohistochemistry 
Preparation and fixation of embryos and tissue 
Embryos and mouse heads from P0 were collected and fixed on ice in 4% 
paraformaldehyde in 1X PBS (pH 7.2) for 1 to 24 hr at room temperature. Embryos were 
fixed for 2 hr to overnight. All harvested tissues were washed three times in 1X PBS (pH 
7.2 for quick rinse, 30 min and 1 hr) and placed in 20% sucrose overnight. On the next 
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morning embryos and tissues were embedded in optimal cutting temperature compound 
(O.C.T.) (Sakura Finetek, Torrance, CA) on dry ice and stored at -80°C until 
cryosectioning. Tissue cryosections of 7 µm were prepared for immunohistochemistry 
and beta galactosidase staining. Embryos and tissues used for beta galactosidase staining 
were fixed on ice for 1 hr in 2% paraformaldehyde and 0.2% glutaraldehyde in 1X PBS 
(pH 7.2). Fixed embryos and tissues were washed three times in 1X PBS (pH 7.2; quick 
rinse, 1 hr, and 30 min) on ice and placed in 20% sucrose at 4°C overnight. 
Beta galactosidase activity detection 
After fixation and washing as described above, pre-fixed embryos were incubated 
at room temperature overnight with gentle agitation in X-gal solution (in 1X PBS (pH 
7.2)), 35 mM potassium ferricyanide, 35 mM potassium ferrocyanide, 2 mM MgCl2, 0.2% 
each of Triton X-100, Nonidet P-40 and Tween 20, and 0.5 mg/ml X-gal diluted in 
dimethylformamide). After X-gal staining, embryos were washed in 1X PBS (pH 7.2) at 
room temperature 2 hr to overnight with gentle agitation. Washed embryos were imaged 
for surface staining. To remove background X-gal staining, embryos were transferred to 
polypropylene tube and dehydrated at room temperature in 70% (30 min), 95% (30 min), 
and 100% ethanol (20 min or overnight). Dehydrated embryos were incubated in 100% 
methyl salicylate at room temperature for 1 hr. Imaging was done rapidly after the 
clearing steps. Single heterozygous littermates served as negative controls.   
Frozen sections for beta galactosidase activity staining were air dried for 5 min 
and fixed for 10 min with 0.5% glutaraldehyde in 1X PBS (pH 7.2) then washed three 
times in 1X PBS (pH 7.2; quick rinse, 10 min, and 5 min) followed by staining in X-gal 
solution (described above) at room temperature in the dark for 2 hr or overnight with 
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gentle agitation. Following staining, the slides were washed three times in 1X PBS (pH 
7.2; quick rinse, 1 hr, 1 hr or overnight). After PBS washing, X-gal stained slides were 
dehydrated in ethanol washes (70%, 80%, 95%, and100%; two times each for 30 sec) and 
then eosin counterstained (Sigma-Aldrich; 1 time 3 min) and then washed in 100% 
ethanol and allowed to dry. After drying, slides were cover-slipped using Permount 
(Fisher Scientific, Pittsburg, PA).  
Immunohistochemistry 
Frozen pituitary and embryo sections were air dried, rehydrated in 1X PBS (pH 
7.2). Antigen retrieval was performed by citrate boil [10 min boiling in10 mM citric acid 
(pH 6.0)] methods. Slides were washed in 1X PBS (pH 7.2) and blocked with 10% 
normal goat serum, 1% BSA and 0.1% Triton X-100 in PBS (pH 7.2) for 20 min at room 
temperature and then incubated with the primary antibodies: rabbit anti-ACTH (1:500 
Fluor) (1:1000 DAB) (AFP-39032082), rabbit anti-αGSU (1:100 Fluor) (1:500 DAB) 
(AFP-66P9986), rabbit anti-LHβ (1:500 Fluor) (1:800 DAB) (AFP-571292393), guinea 
pig anti-LHβ (1:400 Fluor) (AFP-22238790), rabbit anti-FSHβ (1:500 Fluor) (AFP-
77981289), rabbit anti-PRL (1:100 Fluor) (AFP-131078), rabbit anti-TSHβ (1:500 Fluor) 
(1:1000 DAB) (AFP-1274789), rabbit anti-GH (1:500 Fluor) (1:1000 DAB) (AFP-
5672099) (all antibodies from the National Hormone and Pituitary Program, Torrance, 
CA), mouse anti-ISL1 (1:50 Fluor, Developmental Studies Hybridoma Bank (DSHB), 
University of Iowa 39.4D5), rabbit anti-PIT-1 (1:500 Fluor) (Voss et al., 1991), rabbit 
anti-SF1 (1:1000 Fluor) from Dr. Gary Hammer, University of Michigan, guinea pig anti-
GATA2 (1:1000 Fluor) (Peng et al., 2007) from Dr. Kamal Sharma, University of 
Chicago, mouse anti-HB9 (1:100 Fluor, DSHB 81.5C10), guinea pig anti-CHX10 
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(1:1000 Fluor) (Thaler et al., 1999) from Dr. Samuel Pfaff, Salk Institute, rabbit anti-
TPIT (1:200 Fluor) (Lamolet et al., 2001) from Dr. Jacques Drouin, Institut de 
Recherches Cliniques de Montréal, Canada, rabbit anti-β-galactosidase (1:500 Fluor, 
Cappel) and rabbit anti-LIM3/LHX3 (1:100 Flour, Chemicon) as described (Savage et al., 
2007).  
Species-specific biotinylated secondary antibodies and fluorescence avidin kits 
(Texas Red Avidin DCS, Fluorescein Avidin DCS, and AMCA Avidin D) were 
purchased from Vector Labs and used as recommended by the manufacturers. The 
Vectastain Elite ABC kit (Vector Labs) was used for Avidin/Biotin complex detection 
and the Mouse-on-Mouse kit was used (Vector Labs) for detection of mouse primary 
antibodies. For immunofluorescent staining, VECTA shield hard-set mounting medium 
(Vector Labs) was used. 
3, 3΄-diaminobenzidine (DAB) detection was prepared as follow methods: frozen 
sections were rehydrated in 1X PBS (pH 7.2), incubated with 0.3% H2O2 in 100% 
methanol for 20 minutes at room temperature with gentle agitation, then applied followed 
by application of the desired primary antibodies. Peroxidase was visualized by incubation 
with 3, 3΄-diaminobenzidine (DAB) (Sigma). Following DAB immunostaining, slides 
were counterstained with Harris modified hematoxylin (Fisher Scientific) and mounted 
using Permount (Fisher Scientific).  
2.4 Microscopy 
Digital light and fluorescent images of embryo and spinal cord sections were 
captured with a Nikon Eclipse 90i microscope (Nikon Instruments, Inc., Melville, NY) 
with DAPI, FITC, and TRITC filter cubes. Canvas (ACD Systems of America, Inc., 
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Miami, FL) and NIS Elements Vol. 3.2 (Nikon Instruments, Inc.) were used to process 
the images. Light images of whole embryos were obtained using a Leica MZ 6 
microscope and a CCD camera (PL A662, PixeLINK, Ottawa, Ontario, Canada) with 
PixeLINK Capture software.  
2.5 General Molecular Techniques  
Ligations and transformations 
DNA fragments to be ligated were analyzed for size and concentration by agarose 
gel electrophoresis. DNA fragments were joined using 1 μL T4 DNA ligase (Roche) in a 
total volume of 20 μL buffered solution. Ligation mixtures were incubated at 4°C 
overnight. Ten μL of the ligation reaction or 2-5 ng of plasmid preparation were 
transformed into bacterial cells to generate clones. Plasmid DNA was added to 100 μL of 
chemically competent E. coli DH5α cells (Invitrogen) on ice. Transformation of plasmid 
DNA into E. coli using heat shock methods was performed. This mixture was heat 
shocked at 42°C for 1min and placed on ice for 2 min. The addition of 800 μL of LB 
broth supplemented with 0.2% glucose and 10 mM MgCl2 preceded incubation at 37°C 
for 45-60 min with shaking at 220 rpm. After incubation, mixtures were centrifuged at 
1000 rpm for 1 min to pellet the cells. The supernatants were discarded about 700 μL and 
resuspended remaining cells using left supernatants. Suspended cells were plated on LB 
agar plates containing the appropriate selective antibiotic. 
Small scale alkaline lysis plasmid preparation 
E. coli DH5α transformants were incubated at 37°C with shaking overnight in LB 
broth with appropriate antibiotics. To pellet cells, 2 mL of liquid culture was centrifuged 
at 16,000 x g for 1 min. The supernatant was aspirated and the pellet was resuspended in 
  39 
100 µL hypertonic solution 1 (50 mM Tris-HCl, pH 8.0, 0.9% glucose, 10 mM EDTA) 
and allowed to incubate on ice for 5 min. The addition of 200 μL lysis buffer, solution 2, 
(0.2 M NaOH, 0.5% SDS) lysed the cells by gentle mixing and incubation on ice for 5 
min. 175 µL solution 3 (3 M KOAc, 11.5% (v/v) glacial acetic acid) was added followed 
by an additional incubation on ice for 5 min. The solution was centrifuged at 16,000 x g 
for 10 min followed by the addition of 300 µL of phenol/chloroform (1:1) solution and 
centrifugation at 16,000 x g for 10 min. The upper aqueous phase was removed and 1 
volume of room temperature isopropanol was added to precipitate nucleic acids. The 
sample was centrifuged at 16,000 x g for 10 min and the pellet washed with 75% ethanol. 
The pellet was dried at 37°C for 2 min and resuspended in 20 µL TER (100 mg/mL 
RNaseA in 1X TE buffer [10 mM Tris-Cl, pH 7.4, 1 mM EDTA]).  
One to two microliters of extracted plasmid DNA were digested with appropriate 
restriction endonucleases using the recommended buffer and conditions (New England 
Biolabs). Restriction enzyme digest products were visualized on agarose/1X Tris-borate 
gels to select properly constructed plasmids. 
Gel purification of DNA fragments 
DNA fragments to be gel purified were separated on 0.7%, 1.0%, or 1.5% 
agarose/Tris-borate gels. Gel slices containing the fragments of interest were excised as 
quickly as possible using razor blades and long wavelength ultraviolet light. Excision of 
agarose/Tris-borate gel slices was performed by razor blades and done as quickly as 
possible. Gel purification was performed with Qiaquick or MinElute gel extraction 
columns (Qiagen, Valencia, CA) according to the manufacturer’s protocol. Elution from 
the column was performed with either 10 μL (MinElute) or 30 μL (Qiaquick) of the 
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supplied buffer. 
2.6 Quantification and Statistical Analyses 
To quantify LacZ
+
, YFP
+
, and antibody-stained cells in the anterior pituitary and 
spinal cord, at least three comparable sections of each staining were counted for 
positively-labeled cells on cryosections. Individual cells identified by the antibody 
staining were counted and normalized to the number of nuclei observed using Image J 
software. Differences in mean values for each experiment were analyzed with a two-
tailed Student’s t-test. The data were considered significantly different when P<0.05.  
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Figure 2.1. The 3′ human LHX3 enhancer region and the heat shock protein 68 (HSP68) 
promoter were inserted into the modified pBS594-EGFP-Cre vector as shown. EGFPcre 
recombinase expresses depend on enhancer; mouse metallothionein MT-I region 
including the polyadenylation site and several introns (MT-I (A)n); murine H19 insulator 
regions (H19 ins).   
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CHAPTER THREE 
IN VIVO ANALYSIS OF HUMAN LHX3 ENHANCER REGULATION 
3.1 Results 
The 3′ Human LHX3 enhancer reporter gene and the endogenous mouse LHX3 protein 
are co-expressed in anterior pituitary αGSU cell lineages, but not in GH cells 
Our lab previously characterized a 7.9 kb region of 3′ of the human LHX3 gene 
that directs tissue-specific expression to the pituitary gland and spinal cord in a pattern 
consistent with endogenous gene expression. To characterize the activity guided by the 3′ 
7.9 kb enhancer of the human LHX3 gene at the cellular level, enhancer-directed beta 
galactosidase transgene expression was determined in tandem with 
immunohistochemistry for pituitary hormone proteins and the endogenous mouse LHX3 
protein (Mullen et al., 2012). Serial frozen sections were stained for either beta 
galactosidase activity and mouse LHX3 protein or double immunohistochemistry was 
performed using antibodies against hormone subunits (GH, ACTH, αGSU, TSHβ, and 
LHβ) and the mouse LHX3 protein (Figure 3.1 A). The immunohistochemistry 
experiments showed that enhancer transgene-guided LacZ expression was co-localized 
with αGSU-positive cells but not GH somatotropes in the pituitary glands at e17.5 and 
postnatal day 0 (P0) (Figure 3.1 A; h, i, j, m, n, and o). Endogenous LHX3 protein was 
found to co-localize with αGSU-, TSHβ-, and LHβ- expressing cells, but not GH-positive 
cells (Figure 3.1 A; a-e).   
The observation that the enhancer transgene activity and the endogenous LHX3 
protein were not detected in GH cells was intriguing considering that both Lhx3 knockout 
mice and human patients with LHX3 mutations exhibit GH deficiencies.    
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Generation of 3′ LHX3 enhancer-HSP68-Cre (ELHX3Cre) transgenic mice 
 One possible explanation for the lack of reporter activity in the GH cells is that 
LHX3 may be only transiently expressed in these cells and thus at the time points we 
examined the endogenous LHX3 and enhancer directed reporter activity may have been 
silent. In order to determine which pituitary cell types exhibited enhancer-directed 
expression in the developing pituitary, I generated 3′ LHX3 EnhancerCre (ELHX3Cre) 
transgenic mice to characterize enhancer-directed pituitary and neuronal cell lineages. A 
schematic diagram shows generation of ELHX3
Cre
 (human LHX3 gene 3’ enhancer-
HSP68-Cre) transgenic mice and crossing to ROSA26 reporter strains to reveal enhancer-
driven activities (Figure 3.1 B). ELHX3
Cre
 mice were crossed to reporter mice for 
conditional activation of reporter gene expression including ROSA26R
LacZ
 (Soriano, 
1999), ROSA26R
YFP 
(Srinivas et al., 2001), or ROSA26
eGFP-DTA 
mice (Ivanova et al., 
2005). These animals carry LacZ, yellow fluorescent protein (YFP), or diphtheria toxin A 
(DTA) “reporter genes” that are activated in the presence of Cre recombinase activity 
thus marking Cre-expressing cells from that time point onward (Figure 3.1 B). The 
ELHX3
Cre
 transgenic mouse model therefore provides a valuable tool for studies of 
LHX3-associated pituitary hormone cell lineage determination during development. 
The 3′ enhancer from the human LHX3 gene directs Cre recombinase expression in the 
developing and neonatal anterior pituitary and spinal cord 
 Several enhancer-Cre founder animals were crossed to Cre-dependent reporter 
mice and analyzed for LacZ, YFP or DTA activity in the developing pituitary and spinal 
cord. In preliminary LacZ reporter experiments, I identified two enhancer-Cre founder 
lines with anterior pituitary and spinal cord expression patterns similar to those of the 
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original enhancer-LacZ transgenic mice patterns (Mullen et al., 2012). Frozen sagittal 
sections from single heterozygous ELHX3
+/+
/R26
LacZ/+
 mice pituitaries (as negative 
controls) and double heterozygous ELHX3
Cre/+
/R26
LacZ/+ 
(Cre-expressing) pituitary glands 
were analyzed at e14.5 (Figure 3.2 A, B) and P0 (Figure 3.2 C-F) in mice carrying either 
LacZ (Figure 3.2 A, B, C, D) or YFP (Figure 3.2 E, F) reporter genes. Beta galactosidase 
and YFP were expressed specifically in the developing anterior pituitary in 
ELHX3
cre/+
/R26R
LacZ/+ 
and ELHX3
cre/+
/R26R
YFP/+ 
mice but not controls.  
Whole mount staining at e12.5 displayed beta galactosidase activity in the 
developing spinal cord and pituitary (Figure 3.2 H). Some beta galactosidase activity also 
was detected in the retina, hindbrain, and forebrain consistent with the known locations 
of LHX3s (Sheng et al., 1996; Sharma et al., 1998; Sloop et al., 2000a; Sloop et al., 
2000b). Some additional likely ectopic expression was seen in the 
facial/vestibuloacoustic ganglion complex of the nervous system. In subsequent 
experiments, one line of transgenic ELHX3
Cre/+
 mice was used. 
αGSU hormone cell lineages are reduced in ELHX3cre/+/R26RDTA/+ mice 
Double immunohistochemistry of the pituitary gland showed that, similar to the 
data described above from enhancer-LacZ transgenic mice, beta galactosidase expressing 
cells are co-localized with αGSU cells but not GH-positive cells in enhancer Cre 
transgenic mice (Figure 3.1 A). To further test the role of the 3′ enhancer progenitor cells, 
a cell ablation method was performed using the ROSA26
eGFP-DTA
 (R26
DTA
) mice (Ivanova 
et al., 2005). R26
DTA 
mice encode an attenuated form of diphtheria toxin fragment A 
(DTA). When Cre is present, the DTA kills the cells. This approach is useful to 
investigate gene expression-cell lineage relationships. We crossed ELHX3
Cre 
to the 
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R26
DTA 
strain so that enhancer-guided Cre activity would result in DTA expression 
causing cell death in the absence of Cre. Expression of DTA is prevented by a strong 
transcriptional stop signal but when bred to ELHX3
cre/+ 
mice, Cre-mediated excision of 
the floxed stop activates DTA expression to ablate 3′ enhancer-expressing cells. Frozen 
pituitary sections from ELHX3
+/+
/R26
DTA/+
 (as negative controls; Figure 3.3 A, C, E, G, I) 
and ELHX3
Cre/+
/R26
DTA/+ 
(Figure 3.3 B, D, F, H, J) mice at e14.5 were stained with 
antibodies specific for αGSU, TSHβ, ACTH, hormones; or the PIT-1 and TPIT 
transcription factor proteins; and protein expression was revealed using with DAB 
chemistry (Figure 3.3 A-D) and immunofluorescence methods (Figure 3.3 E-J). In these 
experiments, immunohistochemistry of e14.5 embryo pituitary glands revealed a notable 
reduction in αGSU-positive cells in the caudomedial portion of the developing anterior 
pituitary (AP) compared to controls, but αGSU-expressing cells in the rostral tip region 
of the AP were largely retained (Figure 3.3 A, B). Similar patterns were observed using 
antibodies recognizing TSHβ (Figure 3.3 C, D). Anti-TSHβ staining at e14.5 in the 
caudomedial region revealed weak TSHβ expression in ELHX3+/+/R26DTA/+ mice. 
Caudomedial TSHβ cells start to appear approximately at e14.5, and the tested e14.5 time 
point may perhaps be a little early to fully observe caudomedial TSHβ cells. However, 
TSHβ expressing cells are notably reduced in the caudomedial region, but not in the 
rostral tip area, in ELHX3
Cre/+
/R26
DTA/+
 mice. These data suggest that the 3′ enhancer 
expressing αGSU cell lineages in the caudomedial region are ablated in 
ELHX3
Cre/+
/R26
DTA/+
 mice.  
The PIT-1 transcription factor is critical for establishment of the thyrotrope, 
lactotrope and somatotropes cell types in the caudomedial area (Dasen et al., 1999; Scully 
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et al., 2000); by contrast, an earlier thyrotrope population in the rostral tip region is PIT-
1-independent (Lin et al., 1994). PIT-1 expression levels were not notably reduced in 
ELHX3
Cre/+
/R26
DTA/+
 mice at e14.5 (Figure 3.3 E, F). I also examined whether 3′ LHX3 
enhancer-guided DTA activity is target in corticotropes, which secrete ACTH. ACTH 
hormone levels were unaffected (Figure 3.3 C, D). In accord with this observation, levels 
of the TPIT T-box transcription factor that is necessary for corticotrope differentiation 
(Pulichino et al., 2003) were similar in e14.5 ELHX3
Cre/+
/R26
DTA/+
 embryos and controls 
(Figure 3.4 G, H). 
Thyrotrope and gonadotrope cells are reduced in neonatal LHX3
Cre/+
/R26
DTA/+ 
mice 
To examine the expression patterns of pituitary hormone-expressing cells in 
neonatal (P0) mice, transverse pituitary sections were used for immunohistochemistry 
analysis. The numbers of ACTH, TPIT, PIT-1, and GH-positive AP cells were not 
notably changed in ELHX3
Cre/+
/R26
DTA/+ 
mice compared to ELHX3
+/+
/R26
DTA/+ 
controls 
(Figure 3.4 J-R). However, a majority of αGSU- and TSHβ-expressing cells were absent 
in ELHX3
Cre/+
/R26
DTA/+ 
mice (Figure 3.4 A-D). FSHβ-positive gonadotrope cells were 
moderately reduced (Figure 3.4 E, F) and LHβ-expressing gonadotrope cells were 
strikingly lower in number (Figure 3.4 G, H) with some animals having no detectable 
LHβ protein expression (Figure 3.4 I). Overall, these experiments indicate that the 3′ 
human LHX3 enhancer is most active in the mouse thyrotrope and gonadotrope AP cell 
lineages that also express the αGSU subunit hormone component. 
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The majority of ablated gonadotropes in ELHX3
Cre/+
/R26
DTA/+ 
mice
 are LHβ-expressing 
cells that also express FSHβ and SF1 
Because the LH-expressing gonadotropes were the cell type most strikingly 
affected by human LHX3 enhancer-guided DTA activity, I next focused on a closer 
examination of pituitary gonadotropes in the transgenic and control mice. LHβ-
expressing gonadotropes are strikingly ablated in ELHX3
Cre/+
/R26
DTA/+ 
mice with ~90% 
of the cells missing compared to controls (Figure 3.5 A, C). Similarly, a large fraction of 
the αGSU-expressing cells are missing (Figure 3.4 A, B) but a majority (~80% of total 
FSHβ) of FSHβ cells remain (Figure 3.5 A, C).  
Immunofluorescence staining experiments also were performed using anti-LHβ 
and anti-FSHβ antibodies at P0 to characterize bi-hormonal (FSHβ- and LHβ-expressing) 
gonadotropes in the developing mouse pituitary. Most LHβ cells are FSHβ-expressing bi-
hormonal cells (Figure 3.5 A, C). Overall, the FSHβ-expressing, LHβ-negative (“single 
positive”) cells form a majority of the gonadotrope cell population compared to LHβ cell 
numbers. In ELHX3
Cre/+
/R26
DTA/+
 mice, most (~90%) of the bi-hormonal cells are 
removed by DTA action. These data suggest that the human LHX3 enhancer-DTA actions 
preferentially target the bi-hormonal gonadotrope cells (Figure 3.5 C). When single FSHβ 
staining was performed in transgenic animals, ~20% of FSHβ cells were reduced (Figure 
3.4 E, F) and these affected FSHβ cells are bi-hormonal cells. Taken together, our results 
suggest that the 3′ LHX3 enhancer is active in LHβ-expressing bi-hormonal 
gonadotropes. 
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The SF1 transcription factor is expressed in LHβ-expressing gonadotropes and is notably 
reduced in ELHX3
Cre/+
/R26
DTA/+ 
mice 
SF1 is an essential transcription factor for gonadotrope function in mice and Sf1 
knockout mice are infertile and lack gonadotropes (Ingraham et al., 1994; Parker, 1998; 
Zhao et al., 2001). Using anti-SF1 antibodies, double immunofluorescence staining with 
SF1 and FSHβ or LHβ was performed. I observed that SF1 is co-expressed in LHβ cells 
and FSHβ-positive bi-hormonal gonadotropes and SF1-expressing cells are notably 
reduced in ELHX3
Cre/+
/R26
DTA/+ 
mice (Figure 3.5 B; b and d). In wild type mice, virtually 
all LHβ-positive cells were also positive for SF1. By contrast, FSHβ cells were not 
always SF1-positive. We also detected a few SF1-positive cells that do not co-express 
either LHβ or FSHβ (Figure 3.5 B; c and d). The majority of double SF1 and LHβ 
positive cells are absent in ELHX3
Cre/+
/R26
DTA/+
mice (Figure 3.5 B; c and d). This result 
again is consistent with the hypothesis that the 3′ human LHX3 enhancer is especially 
active in LHβ-expressing gonadotropes. Similarly, SF1 expression is co-localized in LHβ 
cells in wild type animals and therefore a significant fraction of SF1 expression is 
reduced in ELHX3
Cre/+
/R26
DTA/+ 
mice. 
LHX3-expressing interneurons are deleted in the mediolateral region of the developing 
spinal cord in ELHX3
Cre/+
/R26
DTA/+
 mice 
V2 INs in the ventral spinal cord are derived from a common progenitor 
population expressing LHX3 (Peng et al., 2007), and are subdivided into two classes: 
V2a INs, which are characterized by expression of the CHX10 transcription factor 
marker, and V2b INs, which express GATA2 and GATA3 (Ericson et al., 1997; Zhou et 
al., 2000; Karunaratne et al., 2002; Smith et al., 2002). During V2 IN specification, 
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LHX3 forms the V2 IN “tetramer complex” consisting of LHX3 and the nuclear LIM 
domain interactor, NLI (Al-Mosawie et al., 2007; Lundfald et al., 2007; Peng et al., 
2007). In order to specify MNs, LHX3 participates in a multiprotein gene regulatory 
complex involving ISL1, NLI, and the NeuroM and E47 transcription factors. MNs are 
characterized by expression of the ISL1 and HB9 homeodomain proteins (Pfaff et al., 
1996; Saha et al., 1997; Tanabe et al., 1998; Thaler et al., 1999). ISL1 is found in MNs, 
dorsal INs, and dorsal root ganglion (DRG) sensory neurons (Liem Jr et al., 1997); 
whereas HB9 is a restricted MN marker (Thaler et al., 1999). To examine whether the 
human 3′ LHX3 enhancer is active during specification of MNs and V2 INs, we 
characterized expression of the ISL1 and HB9 protein for MNs and the CHX10 and 
GATA2 for protein V2 INs in ELHX3
+/+
/R26
DTA/+
 controls and 
ELHX3
Cre/+
/R26
DTA/+
mice. For nervous system analysis, transverse sections of e14.5 
embryos were used to examine the neural tube and sagittal sections were used to visualize 
the spinal cord in the other axis. First, I tested LHX3 protein expression levels in 
ELHX3
Cre/+
/R26
DTA/+ 
in the developing nervous system. LHX3 expression was reduced in 
the mediolateral in mid cervical region of the spinal cord of ELHX3
Cre/+
/R26
DTA/+ 
mice 
(Figure 3.7 A, B). Similar data were collected in transverse sections of the spinal cord 
withLHX3-positive cells diminished in the presumptive V2 IN specific area, but not in 
the presumptive MNs in the spinal cord (Figure 3.6 C, D). Next, I tested ISL1 and HB9 
expression levels in ELHX3
Cre/+
/R26
DTA/+
 mice. HB9 and ISL1-expressing cells in the 
ventral MN area were not notably affected but ISL1-expressing INs were reduced in 
ELHX3
Cre/+
/R26
DTA/+
 mice (Figure 3.7 E-H). These data suggest that INs, not MNs, are 
targeted by 3′ LHX3 enhancer-DTA activity in ELHX3Cre/+/R26DTA/+ mice.  
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LHX3 and CHX10 co-expressing V2a IN cells are reduced in the spinal cord of 
ELHX3
Cre/+
/R26
DTA/+
 mice 
To further investigate the loss of LHX3-expressing cells in the V2 IN area, LHX3 
and CHX10 double immunofluorescent staining was performed. V2a and V2b INs can be 
identified by expression of CHX10 or GATA2/3, respectively. These markers are 
expressed in the intermediate part of neural tube (Al-Mosawie et al., 2007; Lundfald et 
al., 2007; Peng et al., 2007). I observed that ablated LHX3 cells are located in the region 
of V2 INs (Figure 3.7 B, E). LHX3 and CHX10 co-localize in the V2 INs area in 
ELHX3
+/+
/R26
DTA/+ 
controls, but V2a IN CHX10-expressing cells were reduced in 
ELHX3
Cre/+
/R26
DTA/+ 
mice (Figure 3.7 A, D). This data suggests that LHX3 and CHX10
 
co-expressing cells are targeted in ELHX3
Cre/+
/R26
DTA/+
. Together, these observations 
suggest that the human 3′ LHX3 enhancer is active in mouse V2a INs but not in MNs. 
Similar V2a IN data have been described by another laboratory in transgenic animals 
expressing a Chx10 promoter-DTA transgene; these mice exhibited defects in left-right 
coordination and died shortly after birth due to respiratory defects (Crone et al., 2008; 
Crone et al., 2009). Our ELHX3
Cre/+
/R26
DTA/+ 
embryos typically contained pituitary 
glands that were morphologically normal, although these embryos were found at lower 
frequencies than predicted, indicating some prenatal loss of viability (Table 3.1). 
Furthermore, the very few surviving ELHX3
Cre/+
/R26
DTA/+ 
mice were smaller (n=1) than 
littermates (Table 3.1). 
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In ELHX3
Cre/+
/R26
DTA/+ 
mice, GATA2-expressing cells are reduced in the caudomedial 
region of the developing pituitary gland but not in the spinal cord 
The GATA2 transcription factor is expressed in several tissues including the 
developing pituitary (Dasen et al., 1999; Suh et al., 2002), and in the developing nervous 
system where it is known as a V2b IN marker (Zhou et al., 2000). In the developing 
pituitary, GATA2 has been shown to be involved in the differentiation of gonadotrope 
and thyrotrope cell types in a mechanism suggested to involve interactions with the PIT-1 
transcription factor (Dasen et al., 1999; Suh et al., 2002). GATA2 expression therefore is 
observed in developing gonadotropes and in the PIT-1-dependent thyrotropes in the 
caudomedial region of the developing AP (Dasen et al., 1999). 
To determine whether GATA2 expression is affected in the developing pituitary 
and spinal cord of ELHX3
Cre/+
/R26
DTA/+
mice, e14.5 embryo frozen sections were probed 
with an anti-GATA2 antibody. Compared to controls, GATA2-positive cells were 
reduced in the caudomedial portion of the developing pituitary, but not in the rostral tip 
area (Figure 3.8 A, B), a similar pattern to that observed for αGSU staining (Figure 3.3 A, 
B). In the developing nervous system, no notable differences in GATA2 expression were 
detected in DTA-expressing or control mice (Figure 3.8 C, D). This data suggests that the 
human 3΄ LHX3 enhancer is active in GATA2-positive/αGSU-positive cell lineages in the 
developing pituitary and in CHX10-positive V2a INs in the developing nervous system.  
ELHX3
Cre/+
/R26
DTA/+
mice have low viability  
“Double heterozygous” ELHX3Cre/+/R26DTA/+ mice were produced from enhancer-
HSP68-Cre (ELHX3
Cre
)
 
transgenic and homozygous R26
DTA/DTA 
mice. These double 
heterozygous mice have low viability both prenatally and postnatally (Table 3.1). To 
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date, there only three double heterozygous mice have survived. One of these died before 
weaning (postnatal day 21) due to unknown reasons. This mouse was much smaller than 
control littermates. All of the surviving mice were male. One of the two remaining mice 
was dwarfed (Figure 3.9), showed no detectable hearing impairment (could respond to 
noises), and slow moving and had an apparent balance impairment based on observation 
of movement. Whole pituitaries, seminal vesicles, and testes were isolated from control 
and this surviving dwarf ELHX3
Cre/+
/R26
DTA/+ 
mouse and the isolated organ sizes were 
proportionally reduced in ELHX3
Cre/+
/R26
DTA/+
 (Figure 3.9 and data not shown). The 
other surviving male mouse (n=1) was of normal size and fertile. 
Immunohistochemistry performed at 12 weeks of age on the pituitary from the 
surviving ELHX3
Cre/+
/R26
DTA/+
 dwarf mouse revealed that there were no significant 
hormone deficiencies including FSHβ and GH compared to control littermates. However, 
it is important to note that this was one, rare surviving animal that may not be 
representative of a typical outcome.   
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Figure 3.1. The endogenous mouse LHX3 protein and a human LHX3 gene 3′ enhancer-
guided reporter gene are expressed in anterior pituitary αGSU-expressing thyrotrope and 
gonadotrope cells, but not in somatotropes and corticotropes. A. Frozen transverse 
pituitary sections from newborn (P0) (a-j) and e17.5 (k-o) 3’ human LHX3 gene 
enhancer-HSP68-nLacZ transgenic mice were stained by immunohistochemistry for 
LHX3 (green) (a-e) or stained for transgene-derived β-galactosidase activity (blue) (f-o) 
and co-labeled for hormone subunits (red or brown): GH (a, f, k), ACTH (b, g, l), αGSU 
(c, h, m), TSHβ (d, i, n), and LHβ (e, j, o). Co-localization was highest (arrowheads) for 
gonadotropes and thyrotropes (c, d, e, h, i, j, m, n, o) and nearly absent (arrowheads) for 
corticotropes and somatotropes (a, b, f, g, k, l). All experiments were performed a 
minimum of three times. B. Schematic diagram showing generation of ELHX3
Cre
 (human 
LHX3 gene 3' enhancer-HSP68-Cre) transgenic mice and crossing to ROSA26 reporter 
strains to reveal enhancer-driven activities. ELHX3
Cre
 mice were crossed to reporter mice 
for conditional activation of LacZ, YFP, or DTA “reporter” gene expression.  
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 Figure 3.2. The 3′ enhancer from the human LHX3 gene directs Cre recombinase 
expression in the developing and neonatal anterior pituitary and spinal cord. Frozen 
sagittal sections from ELHX3
+/+
/R26
LacZ/+
 (negative control) and ELHX3
Cre/+
/R26
LacZ/+ 
(Cre-expressing) pituitary glands were analyzed at e14.5 (A, B) and P0 (C-F) in mice 
carrying either LacZ (A-D) or YFP (E, F) reporter genes. G and H, X-gal stained whole 
embryos at e12.5 show enhancer-driven LacZ activity in the developing pituitary and 
spinal cord (arrows). Ectopic expression is also seen in some other tissue such as the 
facial/vestibuloacoustic ganglion complex (arrowhead); G, single heterozygous 
ELHX3
+/+
/R26
LacZ/+
 mice as controls (n = 3), H, double heterozygous 
ELHX3
Cre/+
/R26
LacZ/+ 
mice (n = 5). P, posterior lobe of the pituitary gland; I, intermediate 
lobe; A, anterior lobe. 
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Figure 3.3. The human 3′ LHX3 enhancer is active in many αGSU-expressing anterior 
pituitary cells: αGSU cells are notably reduced in the developing pituitary glands of 
ELHX3
Cre/+
/R26
DTA/+
 mice. Frozen pituitary sections from e14.5 ELHX3
+/+
/R26
DTA/+
 (as 
negative controls; A, C, E, G) and ELHX3
Cre/+
/R26
DTA/+ 
(B, D, F, H) mice were stained 
with antibodies specific for αGSU (A, B), TSHβ (C, D), ACTH (E, F), PIT-1 (G, H), and 
T-PIT (I, J) proteins and expression was revealed using either DAB chemistry (A, B) or 
immunofluorescence (C-H). Arrows indicate positively-stained cells. P, posterior lobe, I, 
intermediate lobe, A, caudomedial region of the anterior lobe; R, rostral tip region of the 
anterior lobe.  
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Figure 3.4. Thyrotrope and gonadotrope cell lineages are reduced in neonatal 
ELHX3
Cre/+
/R26
DTA/+ 
mice. Immunostaining of transverse sections from P0 pituitaries 
reveals reduction of αGSU cells (A, B); TSHβ-positive thyrotropes (C, D) and 
gonadotropes (E-I) in ELHX3
Cre/+
/R26
DTA/+ mice. FSHβ-staining gonadotropes are 
reduced (E, F) and LHβ-expressing gonadotropes are either highly reduced (G, H) or in 
some cases completely ablated (I). Control and enhancer-expressing ELHX3
Cre/+
/R26
DTA/+ 
mice did not have different levels of ACTH (J, K), GH (L, M), or PRL (O, P) hormone-
positive cells in ELHX3
Cre/+
/R26
DTA/+ 
mice at P0. Similarly, levels of the PIT-1 
transcription factor were not notably altered (Q, R). 
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Figure 3.5. LHβ-expressing gonadotropes are strikingly ablated in ELHX3Cre/+/R26DTA/+ 
mice and LHβ cells co-localize with FSHβ and SF1. A, Frozen transverse pituitary 
sections of P0 animals were examined with antibodies to LHβ and FSHβ to determine the 
FSH
+
 and LH
+
 populations present in ELHX3
Cre/+
/R26
DTA/+ mice. FSHβ and LHβ cells are 
predominantly located in ventral area of the pituitary. Most LHβ cells and some FSHβ 
cells are ablated in ELHX3
Cre/+
/R26
DTA/+
 mice (a, b, d, e). B, LHβ cells are predominantly 
FSHβ bi-hormonal cells, and are co-express with SF1 cells (c, f). The SF1 transcription 
factor is expressed in LHβ-expressing gonadotropes and is notably reduced in 
ELHX3
Cre/+
/R26
DTA/+ 
mice. Frozen transverse pituitary sections at P0 were co-
immunostained with antibodies recognizing gonadotrope hormones FSHβ (a, c) or LHβ 
(b, d) (red), the SF1 transcription factor (green), and DAPI stain to reveal nuclei (blue). 
SF1
+
 cells co-localize with FSHβ and LHβ cells, and are reduced in ELHX3Cre/+/R26DTA/+ 
mice (c, d). Bi-hormonal (FSHβ/LHβ) cells are indicated by white arrows and single 
hormone (FSHβ or LHβ) cells are indicated by white arrowheads. C, LHβ-expressing 
cells are strikingly diminished in ELHX3
Cre/+
/R26
DTA/+ 
mice. The graph shows the total 
number of αGSU-, FSHβ-, LHβ-, FSHβ-/LHβ-, SF1-, LHβ-/SF1-, and FSHβ-/SF1-
expressing cells compared to controls. Experiments were carried out in control 
ELHX3
+/+
/R26
DTA/+
 littermates (n = 3) and ELHX3
Cre/+
/R26
DTA/+ 
(n = 3). Data are 
expressed as means ± SEM. Differences are significant at the following levels as 
determined by a Student’s t test: αGSU (p < 0.002), FSHβ (p < 0.05), LHβ (p < 0.002), 
FSHβ/LHβ (p < 0.02), SF1 (p < 0.02), LHβ/SF1 (p < 0.001), and FSHβ/SF1 (p < 0.01). 
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Figure 3.6. LHX3-expressing IN cells are reduced in the V2 IN region of the developing 
spinal cord in ELHX3
Cre/+
/R26
DTA/+
 mice but MN populations are unaffected. Sagittal (A, 
B) and transverse sections (C-H) of e14.5 spinal cords from ELHX3
+/+
/R26
DTA/+
 (as 
controls) and ELHX3
Cre/+
/R26
DTA/+
 mice were examined with antibodies against to LHX3 
(A-D), or the motor neuron markers HB9 (E, F) and ISL1 (G, H). The arbitrary dotted 
line in panels A and B indicates the mediolateral region of the spinal cord. Large white 
dotted circles in panels C and D indicate the interneuron area and small white dotted 
circles denote the ventral motor neuron area. White arrows show HB9- or ISL1-positive 
cells. Blue arrows indicate the interneuron reduction in ELHX3
Cre/+
/R26
DTA/+
 mice. ML, 
marginal layer of spinal cord; INs, interneurons; v-MNs, ventral-motor neurons; d-MNs, 
dorsal-motor neurons; DRG, dorsal root ganglion.  
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Figure 3.7. LHX3- and CHX10-expressing V2a interneuron cells are reduced in the 
spinal cord of ELHX3
Cre/+
/R26
DTA/+
 mice. Transverse sections from e14.5 
ELHX3
+/+
/R26
DTA/+
 (A, B, C) and ELHX3
Cre/+
/R26
DTA/+
 (D, E, F) mouse spinal cords 
were co-labeled with antibodies to CHX10 (A, D) and LHX3 (B, E). C, F = merged 
channels. CHX10 and LHX3 co-labeled cells are located in the intermediate ventral area. 
V2a interneuron CHX10- and LHX3-positive cells are reduced in ELHX3
Cre/+
/R26
DTA/+ 
transgenic mice (F). INs, interneurons; v-MNs, ventral-motor neurons. 
 
 
 
  65 
 
Figure 3.8. GATA2-expressing
 
cells are reduced in the caudomedial region of the 
developing pituitary gland but GATA2 expression is normal in the embryonic spinal 
cord. Frozen sagittal sections of the pituitary gland (A, B) and transverse sections of the 
spinal cord (C, D) from e14.5 ELHX3
+/+
/R26
DTA/+
 (controls) or ELHX3
Cre/+
/R26
DTA/+
 
mice were stained with an antibody recognizing the GATA2 transcription factor. GATA2 
expression is present in rostral tip area in both types of animal but is lost in the 
caudomedial region in ELHX3
Cre/+
/R26
DTA/+
 mice (B). White dotted “circles” indicate the 
caudomedial area of the pituitary. Arrows point to GATA2-expressing
 
cells in the rostral 
tip area (R). White dotted rectangles indicate GATA2-positive cells in the spinal cord.  
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Figure 3.9. Dwarfism in rare surviving ELHX3
Cre/+
/R26
DTA/+
 mice. A, In comparison to 
“single heterozygous” control mice, “double heterozygous” ELHX3Cre/+/R26DTA/+ present 
with smaller size at P7 and 12 weeks old (n=1). B, Whole pituitaries were isolated from 
12 weeks old mice. Left panel, control; right panel, ELHX3
Cre/+
/R26
DTA/+
. Anterior 
pituitary (AL) and posterior lobe (PL) of 12 weeks old adult ELHX3
Cre/+
/R26
DTA/+
 
pituitary gland is smaller than controls. Asterisks (*) indicate double heterozygous 
ELHX3
Cre/+
/R26
DTA/+
mice. Scale bar = 1 mm.  
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Table 3.1. Genotypes of progeny from ELHX3
Cre/+ 
and R26
DTA/+ 
crosses. For P0 and P21 
mice, breeding pairs were maintained a minimum of four months. The numbers of 
embryos for each genotype at the indicated stages of development are shown. 
a
Two male 
mice were found alive: one is fertile and of approximately normal size; the other is 
dwarfed and infertile. 
b
Dead mouse (male) was smaller than littermates.  
 
 
 
 
 
  
Age (days) 
ELHX3
Cre/+
/R26
DTA/+
 genotype: live (dead) 
ELHX3
+/+/
R26
DTA/+ 
 ELHX3
Cre/+/
R26
DTA/+ 
 
e14.5 29 5 
e17.5 19 3 
P0 47 4 
P21 65 2
a
 (1
b
) 
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 CHAPTER FOUR 
DISCUSSION 
LHX3 is a LIM-homeodomain transcription factor necessary for proper 
development of the pituitary and central nervous system. Patients with mutations in 
coding regions of the LHX3 gene have complex syndromes including combined pituitary 
hormone deficiency and nervous system defects resulting in symptoms such as dwarfism, 
thyroid insufficiency, infertility, and developmental delay. Previously, we demonstrated 
that the human LHX3 gene has a 3′ enhancer region that includes recognition elements for 
ISL1 and PITX1, and can direct transcription in the developing pituitary and spinal cord 
tissues in similar patterns to endogenous LHX3 expression (Mullen et al., 2012).   
To understand enhancer-directed transgene expression, I used 3′ enhancer-LacZ 
mouse models to determine which pituitary hormone-expressing cell types also showed 
enhancer-directed expression and endogenous LHX3 expression. Interestingly, both 
native LHX3 protein expression and 3′ human LHX3 gene enhancer-directed transgene 
were noted in αGSU-expressing cells but not in GH-positive cells in P0 pituitaries 
(Figure 3.1). This data prompted us to make 3′ human LHX3 gene enhancer-Cre mice to 
use the Cre-loxP system to further study the action of the enhancer in pituitary and spinal 
cord development by lineage tracing. The lineage tracing method allows detection of the 
early time points during development where transgene expression occurs. Therefore, 
using ELHX3
Cre
 mice, we can identify anterior pituitary or neuronal cell types in which 
the 3′ enhancer is expressed.   
ELHX3
cre/+
/R26R
LacZ/+
 mice express the β-galactosidase reporter gene in some, 
but not all, anterior pituitary hormone-secreting cells. In the pituitary, the enhancer-DTA 
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activity is mostly active in αGSU-expressing cells: the LHβ-, FSHβ-, and TSHβ-secreting 
gonadotropes and thyrotrope cell types. This expression pattern matches the endogenous 
LHX3 protein and that noted with direct expression of enhancer-LacZ transgenes. 
Enhancer-directed activity (as revealed by “direct” expression of enhancer-LacZ 
transgenes, and “indirectly” via the actions of enhancer-Cre transgenes in LacZ, YFP, or 
DTA reporter mice) and the endogenous protein were not detected in GH-expressing 
pituitary somatotropes, numerically the most abundant hormone-secreting cell type. This 
result was unexpected considering the deficiencies of GH in pediatric CPHD patients 
with LHX3 mutations and Lhx3 knockout mouse embryos.  
There are several possible explanations for these observations. It may be that 
LHX3 is transiently expressed in developing somatotropes and such expression is 
sufficient to guide the determination of this and the related lactotrope lineage. However, 
the 3′ LHX3 enhancer-Cre lineage tracing experiments using LacZ or DTA appear to 
indicate that the tested human 3′ LHX3 enhancer does not play a role in establishing the 
somatotrope lineage. Others have demonstrated that pituitary somatotropes are 
susceptible to Cre-mediated targeting approaches (Nasonkin et al., 2009). This would 
suggest that there are other cis-acting elements involved in human LHX3 gene 
expression. Alternately, LHX3 may not exert its effects on somatotrope development 
directly; rather, it may act indirectly through its expression in surrounding pituitary cells. 
Pituitary cell types are extensively networked and these cell-cell interactions may play 
significant roles in such developmental influences [reviewed in (Lee and Pfaff, 2001; 
Hashimoto et al., 2005; Kelberman et al., 2009; Davis et al., 2010)]. It is important to 
also consider some limitations of these observations. It is possible that there are levels of 
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LHX3 in somatotropes below the level of detection of the immunohistochemistry 
approaches used here. In addition, this study uses a human LHX3 enhancer sequence. It is 
conceivable that the differences in observed pituitary expression represent differences 
between mouse and human LHX3 expression patterns or differences in gene control 
mechanisms between the two species. Several studies have shown that transgene DNA 
sequences, rather than the host animal environment, typically determine the 
transcriptional outcome. For example, the rat gonadotropin releasing hormone receptor 
gene displays the native rat gene expression pattern in transgenic mouse models rather 
than the mouse pattern (Schang et al., 2011; Schang et al., 2013); human aromatase 
promoters guide a “humanized” expression pattern in transgenic mice (Zhao et al., 2012); 
and human genes show human-like expression patterns in transgenic mice (Willson et al., 
2008). The observations here therefore may represent the actions of the human gene 
enhancer sequence rather than the mouse nuclear environment.  
Even within the αGSU-expressing cell lineages that demonstrate activity of the 3΄ 
human LHX3 enhancer, there is spatial specificity of action. Based on the observation of 
αGSU-expressing cells in ELHX3Cre/+/R26DTA/+ mice, LHβ, FSHβ, and TSHβ cell types 
have different expression sensitivities for the 3′ enhancer. At e14.5, TSHβ and αGSU 
cells are reduced only in the caudomedial region, but not the rostral tip TSHβ and αGSU 
cells. This data suggests that enhancer expression in the caudomedial αGSU and TSHβ 
cells different from enhancer activity in the rostral αGSU and TSHβ cells and therefore 
contain different gene-regulatory environments. This result indicates that the enhancer is 
most active in the central caudomedial area of the AP but not in the rostral tip area. 
Within the caudomedial area, the PIT-1 transcription factor is required for establishment 
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of the thyrotrope, lactotrope and somatotrope cell types, but an earlier thyrotrope 
population in the rostral tip region is PIT-1-independent (Dasen et al., 1999). The 
ELHX3
Cre/+
/R26
DTA/+
 experiments demonstrate that the enhancer is not active in most of 
the PIT-1 expressing cells, including the GH, PRL producing cells, since PIT-1 
expression is not dramatically affected by DTA activity. However, the TSHβ-staining 
data suggests that the enhancer is active in central caudomedial area thyrotropes but not 
in the rostral tip thyrotropes. Corticotrope ACTH hormone and corticotrope-restricted T-
box transcription factor TPIT (Lamolet et al., 2001; Pulichino et al., 2003) expression 
levels were not notably reduced in ELHX3
Cre/+
/R26
DTA/+
 mice. This indicates that 
corticotropes are largely unaffected in ELHX3
Cre/+
/R26
DTA/+
 mice and this data correlates 
with the lack of LHX3 in corticotrope cells during mouse anterior pituitary development 
[reviewed in (Drouin et al., 2007)].  
Interestingly, I found that the 3′ human LHX3 enhancer-DTA activity is notable in 
LH-expressing gonadotropes. The pituitary gonadotrope is a complex cell type that 
secretes hormones with multiple actions that are required for many aspects of 
development, physiology, and behavior [reviewed in (Brown and McNeilly, 1999)]. 
However the mechanisms that determine the gonadotrope cell lineage are not fully 
understood. This study is the first to determine the fraction of bi-hormonal FSHβ/LHβ 
cells in gonadotropes in the developing mouse pituitary. Whereas LH-expressing 
gonadotrope numbers were notably affected by human LHX3 enhancer guided DTA 
activity with ~90% of the cells missing compared to controls, the impact on FSHβ-
expressing gonadotropes, although significant, is considerably less and a majority (~80% 
of total FSHβ) remains. I observed the number of FSHβ positive cells is larger population 
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than bi-hormonal (FSHβ/LHβ) gonadotrope cells. The possible physiological role of a 
FSH only cell is that it may be simply a cell that does FSH-related activities [e.g. 
spermatogenesis or gonad development; reviewed in (Simoni et al., 1997)]. Further 
experiments are needed to test FSH level at postnatal stages or puberty period to confirm 
above hypothesis. Previous studies have also examined gonadotrope populations in the 
developing pituitaries. For example, in accord with our results, a study of human 
gonadotropes demonstrated that whereas LH-only cells are very rare (0.1-0.3% of total 
gonadotropes), bi-hormonal and FSH-only cell types are more common (Pope et al., 
2006). Our data suggest that gonadotrope population is mostly composed of bi-hormonal 
(FSHβ/LHβ) and single FSHβ-expressing cells in developing mouse pituitaries and that 
the human LHX3 3′ enhancer-guides gene expression to bi-hormonal gonadotrope cells.  
Multiple pituitary transcription factors contribute to the signals that restrict 
gonadotrope cells to their specific fates [reviewed in (Lee and Pfaff, 2001; Hashimoto et 
al., 2005; Kelberman et al., 2009; Davis et al., 2010)]. For example, recent studies have 
shown that GATA2, LHX3 and ISL1 interact in vivo to regulate rat gonadotropin-
releasing hormone (GNRH) receptor (Gnrhr) promoter activity (Charles et al., 2006; 
Schang et al., 2013). GNRH is expressed in the hypothalamus and is transported to the 
anterior pituitary and binds to the GNRH receptor (GnRHR) in gonadotrope cells. This 
stimulates the synthesis and release of LH and FSH. It is likely that LHX3, GATA2 (and 
perhaps other pituitary-expressed GATA factors such as GATA3 or 4 (Charles et al., 
2006; Lo et al., 2011)), SF1, and ISL1 contribute selectively to establishing different 
gonadotrope subtypes over time. Experiments using Cre targeting under transcriptional 
control of the Gnrhr gene, as similarly observed here for LHX3 enhancer action, 
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demonstrated efficient ablation of LH-expressing but not FSH-positive gonadotropes 
(Wen et al., 2010). These authors also noted that the targeted LHβ positive cells were bi-
hormonal cells that also made FSH and GnRHR. Our data suggest that the 3′ human 
LHX3 enhancer is notably active in LH-expressing gonadotropes and that FSH-only (but 
not bi-hormonal) gonadotropes do not possess a transcriptional milieu that mediates the 
actions of this enhancer. The 3′ human LHX3 enhancer is directing LHX3 expression to 
the appropriate cell types including gonadotrope cells. Further experiments are needed to 
determine the expression of GnRHR in ELHX3
Cre/+
/R26
DTA/+ 
mice and to compare 
expression levels of GnRHR with LHβ and FSHβ. This experiment will give us better 
understanding about the 3′ enhancer-DTA action in gonadotrope subtypes whether 
GnRHR is expressing all gonadotrope cells or only in bi-hormonal cells.  
Our immunohistochemistry analysis showed that the 3′ human LHX3 enhancer-
DTA specifically ablates pituitary cells expressing the GATA2 transcription factor that 
serves as an upstream regulator of gonadotrope lineages. Consistent with the observations 
for αGSU and TSHβ, GATA2 cells were notably reduced in the caudomedial portion of 
the AP rather than in the rostral tip area. In the AP, GATA2 is postulated to be involved 
in the differentiation of gonadotrope and thyrotrope cell lineages (Dasen et al., 1999). 
GATA2 expression is detectable at e10.5 at the ventral boundary of Rathke’s pouch and 
persists through adulthood in an expression pattern coincident with αGSU cells (Dasen et 
al., 1999). It has been shown that GATA2 can activate the expression of SF1 (Steger et 
al., 1994) which in turn stimulates αGSU and LHβ expression, but not FSHβ expression 
(Brown and McNeilly, 1999). In vitro cell transfection assays suggest that GATA2 can 
regulate the human αGSU gene in αT3 gonadotrope cells (Steger et al., 1994) and that 
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inhibition of endogenous GATA2 and GATA4 expression decreases expression of the 
LHβ gene in LβT2 cells (Lo et al., 2011). These studies indicate a role for the GATA2 
transcription factor in regulating LHβ expression. Pituitary-specific Gata2 knockout mice 
are smaller than wild type littermates and contain low levels of thyrotrope and 
gonadotrope cell lineages after birth (Charles et al., 2006). αGSU promoter-DTA tox176 
mice have complete ablation of transcripts of αGSU, TSHβ, and LHβ using in situ 
hybridization detection (Burrows et al., 1996). However, neither αGSU nor GATA2 
positive cells are completely ablated in ELHX3
Cre/+
/R26
DTA/+ 
mice. Taken together, this 
data suggests the interpretation that GATA2 action, either directly or indirectly, is related 
to the actions of LHX3 mediated by the 3′ gene enhancer in the caudomedial region of 
the AP. However GATA2-, αGSU- and TSHβ-expressing cells in the rostral tip area of 
the AP are independent of LHX3 expression guided by the 3′ LHX3 enhancer. The results 
of this study indicate that the enhancer ablation of caudomedial GATA2 cells leads to 
absent or low populations of thyrotropes and gonadotropes, especially LH-expressing 
cells at later embryonic time points. The corticotropes, somatotropes, and lactotropes 
appear to be mostly unchanged in pattern and number in the developing anterior pituitary.  
Bioinformatic searches of potential GATA2 binding sites in 3′ enhancer region of 
the human LHX3 were performed with programs such as MatInspector (Quandt et al., 
1995). There are several putative GATA binding sites in the 3′ enhancer region. Further 
research will be needed to test the role of GATA factor such as GATA2. Experiments 
might include in vivo luciferase assays using LβT2 mouse gonadotrope cells to test if 
GATA2 can increase luciferase activity when co-transfected with 3′ enhancer-luciferase 
constructs. Subsequent mutation of possible GATA2 binding sites would be needed to 
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test whether these GATA2 binding sites are important for gene transcription and which 
GATA2 sites are necessary. In vitro gel shift assay may also be needed to confirm 
GATA2 binds to the possible GATA binding sites in the 3′ enhancer. Chromatin 
immunoprecipitation assays could be performed using embryonic mouse pituitary tissue 
or culture pituitary cells to determine whether GATA factors are present at the indicated 
enhancer sequences. Further to test the function of these GATA2 binding sites using in 
vivo analysis, putative GATA2 binding sites will be mutated in the enhancer in transgenic 
mouse models such as enhancer-LacZ mice. 
From our data, LHβ cells are typically bi-hormonal cells and this bi-hormonal 
population is ~45% of all gonadotrope cells in the developing pituitaries normal mice. In 
addition, I tested SF1 expression in ELHX3
Cre/+
/R26
DTA/+ 
mice. SF1 is known to act 
downstream of Gata2 and SF1 expression is reduced following ablation of GATA2 
(Charles et al., 2006). In normal pituitaries, virtually all LHβ-positive cells are SF1-
positive. By contrast, FSHβ-expressing cells are not always SF1-expressing and a few 
pituitary cells (less than 5% of total SF1-positive cells) are SF1-positive but do not 
express either LHβ or FSHβ (data not shown). We assume that these SF1-only expressing 
cells are gonadotrope precursor cells which may develop after birth or during puberty. 
Out data suggest that the SF1 transcription factor expression is reduced in the remaining 
bi-hormonal gonadotropes in ELHX3
Cre/+
/R26
DTA/+ 
mice.  
Previous studies have shown that LHX3 is expressed in the developing spinal 
cord and is involved in MN and V2 IN specification (Tsuchida et al., 1994; Sharma et al., 
1998; Thaler et al., 2002; Al-Mosawie et al., 2007; Peng et al., 2007). For example, in 
Lhx3::Cre; ROSA26::YFP mice: a Lhx3
Cre
 mice has been generated by inserting Cre 
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cassette into the 3′ UTR of the Lhx3 gene (Sharma et al., 1998), YFP is expressed in a 
subset of V2 INs as well as in MNs at P0 (Sharma et al., 1998; Al-Mosawie et al., 2007; 
Lundfald et al., 2007; Peng et al., 2007). Mice lacking the Lhx3 gene fail to generate 
proper MNs and V2 INs (Sharma et al., 1998). LHX3 appears to be a primary 
transcription factor required to direct specification of V2 INs by forming V2-tetramer 
complex; however MN specification requires both ISL1 and LHX3 in the MN hexamer 
complex (Thaler et al., 2002). Our previous study demonstrated that the 3 LHX3 
enhancer region contains multiple nervous system-specific enhancer modules and 
transcriptional activity guided by the 3′ enhancer is similar to the time frame of 
endogenous LHX3 expression in the spinal cord at e9.5 (Mullen et al., 2012).  
In this study, we showed by 3′ enhancer-Cre-mediated DTA ablation that 
endogenous LHX3 expression is reduced in mediolateral portion of the mid cervical 
region of sagittal spinal cord sections. Also only few LHX3 positive cells are detected in 
the mouse V2a (CHX10-positive; GATA2-negative) glutamatergic excitatory INs 
(Kimura et al., 2006; Lundfald et al., 2007; Peng et al., 2007) area suggesting that the 3′ 
human LHX3 enhancer guides LHX3 expression in this spinal cord cell type. Similar V2a 
IN expression data have been described for transgenic animals expressing a Chx10 
promoter-DTA transgene (Crone et al., 2008; Crone et al., 2009). The number of MNs, as 
determined by HB9 and ISL1 co-expression, were not significantly reduced but ISL1
+
 
INs were notably reduced in ELHX3
Cre/+
/R26
DTA/+ 
mice. These data suggest that 3′ LHX3 
enhancer mediated expression of LHX3 is necessary for V2a IN expression but not MN 
expression. In Lhx3 null mice, ISL1 is still activated at e9.5 (Sheng et al., 1997) and 
suggests that LHX3 is not crucial element for ISL1 expression. It is possible the ISL1 
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alone expression is sufficient to activate MNs in the developing spinal cord or other 
trans-acting factors to LHX3 gene maybe more critical than LHX3 expression guided by 
3′ enhancer. We conclude that other gene regulatory elements are required for LHX3 
expression in MNs.  
In this study, we use R26
DTA
 mice containing a gene encoding an attenuated 
diphtheria toxin A subunit, which has a point mutation that results in a glycine to aspartic 
amino acid substitution at residue 128 (Maxwell et al., 1987). This single amino acid 
substitution makes DTA ~30-fold less active than native DTA (Breitman et al., 1990). 
Attenuated DTA has been used to study cell lineage in the pancreas, pituitary, lens, etc., 
[reviewed in (Saito et al., 2001)]. Studies have shown that transgenic mouse models 
which express attenuated DTA guided by the pituitary αGSU promoter did not affect 
viability and αGSU cells were ablated; LHβ and TSHβ cells were absent, but GH cells 
were not changed (Burrows et al., 1996). Few studies have compared the native 
diphtheria toxin and the attenuated version (Maxwell et al., 1987; Lang and Bishop, 1993; 
Lowell et al., 1993). These studies have suggested that the attenuated toxin is able to 
ablate specific cells without killing many of the transgenic founders. This led to the 
interpretation that our data using DTA mouse model have less bystander cell killing.  
The LHX3 3′ enhancer-mediated DTA cell ablation mouse (ELHX3Cre/+/R26DTA/+) 
model displays extremely low viability (Table 3.1). ELHX3
Cre/+
/R26
DTA/+ 
mice have 
prenatal and postnatal loss. The low viability of ELHX3
Cre/+
/R26
DTA/+ 
mice may have 
several causes include loss of essential LHX3 functions in the pituitary and especially the 
nervous system. Similar pre- and post-natal loss data have been found in Chx10 
promoter-DTA transgenic mice (Crone et al., 2008): mice died shortly after birth or 
  78 
rarely surviving mice were small and exhibited defects in left-right coordination. These 
authors also found that survival of Chx10::DTA mice is strain dependent (Crone et al., 
2009). Furthermore, loss of viability and phenotypic differences associated with genetic 
background have been shown in mouse models of pituitary disease (Nasonkin et al., 
2004; Prince et al., 2013), kidney disease (Han and Strohl, 2000), and V2a interneuron 
ablation (Bradley et al., 2006; Crone et al., 2009), for example. The ELHX3
Cre/+
/R26
DTA/+ 
mice described here are on a C3HeB/FeJ + C3H genetic background. It is possible that 
different genetic backgrounds may result in higher viability or different experimental 
results. 3 enhancer-directed DTA target cells are present not only in the pituitary but also 
in the nervous system, and these ablated cells both in the pituitary and spinal cord may 
induce multiple developmental defects during organogenesis. However the exact cause of 
ELHX3
Cre/+
/R26
DTA/+
 mice phenotype is unknown. One of the possible explanations for 
low viability in ELHX3
Cre/+
/R26
DTA/+ 
mice is that loss of proper interneuron cells or loss 
of the facial/vestibuloacoustic ganglion complex (or loss of cells in ectopically-expressed 
locations) may cause nervous system defects. 
 This study describes cell-specific actions of a downstream enhancer of the human 
LHX3 gene during development of the anterior pituitary and spinal cord. This data 
strongly suggests that the 3′ enhancer region is required for the proper expression of 
LHX3 in specific hormonal cells and neural cells. The 3′ LHX3 enhancer region is 
important for LHX3 expression in GATA2-positive pre-TSHβ, LHβ, and FSHβ hormone 
cells, and V2a INs. This implies it functions in their differentiation by precisely 
controlling LHX3 expression. Specifically LHX3 expression guided by the 3′ enhancer is 
in αGSU-positive/GATA2-positive developing gonadotropes and caudomedial-
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thyrotropes, which are located in the caudomedial region of the anterior pituitary. We 
assume these cells co-express with LHX3. However GH, PRL, ACTH, and rostral tip 
αGSU- and TSHβ-expressing cells are not directly activated by the 3′ enhancer-guided 
LHX3 expression. Additionally, excitatory V2a INs exhibit 3′ enhancer-guided LHX3 
expression in the developing spinal cord. My studies suggest that action of the 3′ 
enhancer plays critical roles in guiding LHX3 expression and subsequent specification of 
specific hormone and neuronal cells during embryogenesis.   
It is possible that mutations in non-coding regulatory regions of the human LHX3 
gene might underlie uncharacterized cases of LHX3-associated CPHD. To date, in 
collaborations with pediatric endocrinologists, we have not discovered any genetic 
changes in LHX3 gene transcriptional regulatory regions that might cause such disease 
but our efforts to characterize the molecular genetic basis of LHX3-associated CPHD 
continue. The ELHX3
Cre 
mouse model will serve as an important tool in these efforts. 
 
Uncovering cell-specific regulation of LHX3 enhancer activity in the pituitary and 
nervous system will provide a clear understanding of the biology of the human LHX3 
gene on a cellular level. 
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